

TO AND TO WHOMSOEVER PRESENTS: SHANIL CONNELL

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

December 09, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 60/518,799
FILING DATE: *November 10, 2003*
RELATED PCT APPLICATION NUMBER: *PCT/US04/37394*

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



BEST AVAILABLE COPY

11/10/13
17175 U.S. PTO

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 C.F.R. § 1.53(c).

	Docket Number	21085.0067U1	Type a Plus Sign (+) inside this box	+
INVENTOR(s)				
LAST NAME	FIRST NAME	MIDDLE INITIAL	RESIDENCE (City and Either State or Foreign Country)	
van Ginkel	Frederik	W.	Homewood, AL 35209	
Briles	David	E.	Birmingham, Al	
Watts	James		Birmingham, Al	
TITLE OF INVENTION (500 characters max)				
"COMPOSITION FOR REDUCING BACTERIAL CARRIAGE AND CNS INVASION AND METHODS OF USING SAME"				
CORRESPONDENCE ADDRESS				
Customer Number 23859				
ENCLOSED APPLICATION PARTS (Check All That Apply)				
 <input checked="" type="checkbox"/> Provisional Application Title Page Number of Pages [1] <input checked="" type="checkbox"/> Specification (includes Description, Claims, & Abstract) Number of Pages [69] <input checked="" type="checkbox"/> Drawing(s) Number of Sheets [5] <input type="checkbox"/> Authorization to Treat Reply Requesting Extension of Time as Incorporating Petition for Extension of Time <input checked="" type="checkbox"/> Other (specify): <u>Table (2 pages)</u>				

METHOD PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (Check One)	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR § 1.27.	FILING FEE AMOUNT <input checked="" type="checkbox"/> A Credit Card Payment Form PTO-2038 is enclosed to cover the filing fees. <input type="checkbox"/> A check or money order is enclosed to cover the filing fees. <input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number _____. <input type="checkbox"/> The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. _____.
<input checked="" type="checkbox"/> A Credit Card Payment Form PTO-2038 is enclosed to cover the filing fees.	
<input type="checkbox"/> A check or money order is enclosed to cover the filing fees.	
<input type="checkbox"/> The Commissioner is hereby authorized to charge filing fees and credit Deposit Account Number _____.	
<input type="checkbox"/> The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. _____.	

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

No.

Yes. The name of the U.S. Government agency and the Government contract number are:
National Institute of Health Grants DC 04976, AI 21548, and P30 DK 54781
National Institute of Allergy and Infectious Diseases Grant NO1 AI 65299

Respectfully submitted,

Signature Gwendolyn D. Spratt Date 11-10-03
Typed or Printed Name: Gwendolyn D. Spratt
Registration No. 36,016

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10	
I hereby certify that this correspondence and any items indicated as attached or included are being deposited with the United States Postal Service as Express Mail, Label No. EV217856818US, in an envelope addressed to: MAIL STOP PROVISIONAL PATENT APPLICATION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Miles E. Hall	Date <u>11/10/03</u>

1
ATTORNEY DOCKET NO. 21085.0067U1

Express Mail No. EV217856818

5

**PROVISIONAL APPLICATION
FOR
UNITED STATES LETTERS PATENT
FOR**

10

**COMPOSITIONS FOR REDUCING BACTERIAL CARRIAGE AND CNS
INVASION AND METHODS OF USING SAME**

15

BY

Frederik W. van Ginkel, Ph.D., citizen of the Netherlands; David E. Briles, Ph.D., citizen of the United States; and James Watts, citizen of the United States, residing at 504 Morris Boulevard, Homewood, AL 35209; 760 Linwood Road, Birmingham, AL 35222; 1827 1st Avenue North, Apartment 213, Birmingham, Al 35203, respectively.

**COMPOSITIONS FOR REDUCING BACTERIAL CARRIAGE AND
CNS INVASION AND METHODS OF USING SAME**

ACKNOWLEDGEMENTS

5 This invention was made with government support under Grants DC 04976, AI 21548, and P30 DK 54781 from the National Institutes of Health and under contract NO1 AI 65299 from the National Institute of Allergy and Infectious Diseases. The government has certain rights in the invention.

BACKGROUND

10 *Streptococcus pneumoniae* is a rather ubiquitous human pathogen, which can infect several organs including lungs, the central nervous system (CNS), the middle ear, and the nasal tract. Infection of these tissues results in various symptoms such as bronchitis, pneumonia, meningitis, and sinus infection. *S. pneumoniae* is a major cause of bacterial meningitis in humans and is associated with significant mortality
15 and morbidity despite antibiotic treatment. Quagliarello et al., (1992) N. Eng. J. Med. 327: 869-872. *S. pneumoniae* meningitis can cause persistent neurological sequelae. The incidence of *S. pneumoniae* meningitis in developed versus developing countries are 1-2 and 20 per 100,000 population, respectively. Anon, (2000) CDSC European Bacterial Meningitis Surveillance Project. The fatality rate of pneumococcal
20 meningitis in the USA is approximately 18 %. Fedson et al., (1994) Arch. Intern. Med. 154:2531-2535. The highest incidence of pneumococcal meningitis occurs in children between 1-4 years of age (30 % of all bacterial meningitis), followed by 15-19 year olds (14 %) and 1-11 month old infants (13 %). Anon, (2000) CDSC European Bacterial Meningitis Surveillance Project. The elderly are also seriously
25 affected by streptococcal meningitis in both developed and developing countries. Butler et al., (1999) Drugs Aging 15 (Suppl. 1): 11-19; Fedson et al., (1999) Vaccine 17 Suppl.1: S11-18.

The major reservoir of pneumococci in the world resides in human nasal carriage. Acquisition of infection is generally from a carrier and infection is always preceded by nasal carriage. The colonization of the nasopharynx is considered a prerequisite for the spread of pneumococci to the lower respiratory tract, the nasal 5 sinuses, and the middle ear. Thus, any medical intervention that prevented carriage would not only eliminate the risk of disease in the treated individuals but would also result in herd immunity and greatly lower the risk of infection even in untreated members of the community. Although *S. pneumoniae* is an important human pathogen, relative little is known about the mechanisms by which *S. pneumoniae* 10 causes either nasal carriage or meningitis.

Some data exist to suggest that neuraminidases are unique virulence factors for the nasal tract. One such observation comes from the study of the NanA-deficient, *S. pneumoniae* strain D39, which is eliminated faster from the nasopharynx than is its parent strain. Tong et al., (2002) *Infect. Immun.* 68: 921-924. Neuraminidase cleaves 15 terminal sialic acid residues from a wide variety of glycolipids, glycoproteins, and oligosaccharides on the host cell surfaces and in body fluids. Elevated levels of free sialic acid in the cerebrospinal fluid (CSF) of patients with pneumococcal meningitis are associated with a poor prognosis. O'Toole et al., (1971) *J. Clin. Invest.* 50: 979-985. The importance of this enzyme for *S. pneumoniae* virulence in humans is further 20 illustrated by the findings of two independent studies where every new clinical isolate of *S. Pneumoniae* had neuraminidase activity. O'Toole et al., (1971) *J. Clin. Invest.* 50: 979-985; Kelly et al., *J. Bacteriol.* 94: 272-273. Moreover, mouse passage of isolates of pneumococci, which frequently increases their virulence, has been reported to also result in 2-5-fold increase of neuraminidase activity. Vishniakova et al., 25 (1992) *Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii* 9-10: 26-9. Pneumococcal C-polysaccharide, also known as teichoic acid, is structurally identical to the polysaccharide portion of pneumococcal F-antigen, also known as lipoteichoic acid. Fischer et al., (1993) *Eur. J. Biochem* 215: 851-857. These molecules are unique features of *S. pneumoniae* among gram-positive bacteria. The

immunodominant determinants on these molecules are the phosphorylcholine (PC) residues and Abs to PC are protective against intraperitoneal, intravenous, or nasal pneumococcal challenge. Briles et al., (1984) *Eur. J. Immunol.* 14: 1027-1030; Briles et al., (1981) *Nature* 294: 88-90; Yother et al., (1982) *Infect. Immun.* 36: 184-188;

5 Briles et al., (1984) *J. Mol. Cell. Immunol.* 1:305-309. However, as all of these studies assessed protection against systemic infection medicated by serum, no information is available regarding the ability of these Abs to protect against nasal colonization. Surface phosphocholine residues are, however, common on the surface of respiratory bacteria. Lysenko, et al., (2000) *Infect. Immun.* 68:1664-71.

10 The mechanisms by which *S. pneumonia* causes nasal carriage and subsequent disease are relatively unknown. Neuraminidase, teichoic acid, and lipoteichoic acid are partially protective against systemic infection following intraperitoneal or nasal pneumococcal challenge. Previous studies, however, assessed protection by systemic administration. Locke et al., (1988) *Microb. Pathog.* 5: 461-467. No studies to date

15 have determined a mechanism by which nasal carriage is reduced or prevented. Since colonization of the nasopharynx is considered a prerequisite for the spread of pneumococci to the lower respiratory tract, the nasal sinus, systemically, and to the brain, what is needed in the art is a means to provide mucosal immunity at the site of initial pneumococcal colonization. Preventing initial pneumococcal colonization in

20 the nasopharynx, will prevent nasal carriage and reduce spread of *S. pneumoniae* between individuals. Moreover, providing immunity at the mucosal surfaces of the nasopharynx prevents or reduces subsequent disease caused by *S. pneumoniae*.

SUMMARY OF THE INVENTION

Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneumococcal infections), nasal carriage, nasal colonization, and CNS invasion. Optionally, the compositions are designed for mucosal administration. Provided herein are detoxified pneumococcal neuraminidase,

phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of any one of these and compositions comprising these detoxified agents.

Also provided are compositions comprising a pneumococcal neuraminidase, 5 phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of any one of these and a pharmaceutically acceptable carrier. Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Also provided are 10 detoxified pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of any one of these as well as compositions containing the detoxified agents and methods of using the agents.

Also provided are methods of generating in a subject antibodies to 15 pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of any one of pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, or pneumococcal lipoteichoic acid comprising administering to the subject a composition comprising the agents. Optionally, the composition is suitable for administration to a mucosal 20 surface or for systemic administration.

Further provided is a composition comprising antibodies to a pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of any one of these, along with a pharmaceutically acceptable carrier. Optionally the composition is suitable for 25 administration to a mucosal surface or for systemic administration.

Further provided are methods of reducing or preventing nasal carriage, nasal colonization, or bacterial infection (for example pneumococcal infection) in a subject

comprising contacting the nasal mucosa of the subject with a composition taught herein.

Additional advantages will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by

5 practice of the aspects described below. The advantages described below will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several aspects described below. Like numbers represent the same elements throughout the figures.

5 Figure 1 shows nasal delivery of 3×10^6 CFU of either the nonencapsulated R36A strain or the virulent EF3030 strain of *S. pneumoniae* to *xid* mice. The neuronal tissues ON/E, OBs, brain and the lymphoid tissues (NALT, CLN and lungs) were collected, minced and analyzed for the presence of live pneumococci at 1 and 4 days after nasal challenge. Indicated is the mean of \log_{10} colony forming units (CFUs) +
10 one standard error (SE). The 0 value on the Y-axis represents the absence of detectable CFUs. Indicated are the mean CFUs + SE of 5 mice per group and are representative of three different experiments.

15 Figure 2 shows the kinetics of organ distribution of *S. pneumoniae* strain EF3030 CFUs after nasal challenge. The ON/E, OBs, brain, blood, NW, NALT, CLN, and lung tissues were collected on days 4, 11, 18, 25, and 39 and were analyzed for the presence of *S. pneumoniae*. An aliquot of 3×10^6 CFU of *S. pneumoniae* resulted in the colonization of the nasal tract and a subsequent infection of the OBs. The 0 value on the Y-axis represents the absence of detectable CFUs. Indicated are the mean CFU + SE of three separate experiments. Each time point represents 10 mice
20 with the exception of day 39, which represents 5 mice.

25 Figure 3 shows the distribution of *S. pneumoniae* strain EF3030 following preincubation with GLSs. Aliquots (3×10^7 CFUs) of *S. pneumoniae* were incubated for 30 minutes with 20 μ g asialo-GM1 (a-GM1) or 125 μ g of mixed GLSs (MG) prior to nasal application. The ON/E, OBs, brain and NW, NALT and lungs were collected four days later and analyzed for numbers of *S. pneumoniae*. The 0 value on the Y-axis represents the absence of detectable CFUs. Indicated are the mean + one SE of 5 mice

and the P-values were obtained following statistical analysis. The data are representative of two separate experiments.

Figure 4 shows detection of the TIGR4 strain of *S. pneumoniae* in the OBs following nasal challenge. An aliquot of 5×10^5 CFU was given nasally and the 5 blood, NWs, ON/E, OBs and brain tissues were analyzed for colonization one week after challenge (panels A and B). These tissues (10 µg DNA) were also analyzed for the presence of the pneumolysin gene by PCR (panel C). In addition, the *S. pneumoniae* were visualized by immunofluorescence with PspA-specific Abs in the OBs of control (D) or *S. pneumoniae* challenged mice (panels E and F). Indicated are 10 the mean + one SE. The data are representative of three separate experiments.

Figure 5 shows inhibition of nasal colonization of *S. pneumoniae* by anti-phosphocholine-specific monoclonal antibodies after nasal challenge. Inhibition of nasal colonization of *S. pneumoniae* by anti-PC-specific mAbs after nasal challenge. A total of 1×10^6 CFU of the TIGR4 strain were incubated with 5 µg of anti-PC 15 mAbs of either the IgG3 subclass or IgM isotype. A total of 5 µl was administered per nare. Indicated are the CFU in 500 µl nasal wash respectively 9 and 12 hours after application. Indicated are the mean + SD of five mice per group.

Figure 6 shows pneumococcal neuraminidase mutants are unable to colonize the nasal tract. Pneumococcal neuraminidase mutant *nanA* is unable to colonize the 20 nasal tract. The neuraminidase mutant of *nanA*, *nanB*, or the double mutant *nanA/nanB* were administered at 5×10^5 CFU in 10 µl nasally in unanesthetized mice and were compared with the wildtype strain, TIGR4. After six days the nasal wash, olfactory nerves and epithelium (ON/E), olfactory bulbs (OBs) and blood were analyzed for CFUs. As illustrated above no nasal colonization or invasion into OBs 25 was observed. Indicated are means + SD of 3-4 mice per group.

DETAILED DESCRIPTION

Before the present compounds, compositions, articles, devices, and/or methods are disclosed and described, it is to be understood that the aspects described below are not limited to specific synthetic methods or specific administration methods, as such 5 may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting.

It must be noted that, as used in the specification and the appended claims, the singular forms "a," "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an antigenic fragment" includes 10 mixtures of antigenic fragments, reference to "a pharmaceutical carrier" or "adjuvant" includes mixtures of two or more such carriers or adjuvants, and the like.

As used throughout, by a "subject" is meant an individual. Thus, the "subject" can include domesticated animals, such as cats, dogs, etc., livestock (e.g., cattle, 15 horses, pigs, sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, rat, guinea pig, etc.) and birds. In one aspect, the subject is a mammal such as a primate or a human.

"Optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, the 20 phrase "optionally the composition can comprise a combination" means that the composition may comprise a combination of different molecules or may not include a combination such that the description includes both the combination and the absence of the combination (i.e., individual members of the combination).

Ranges may be expressed herein as from "about" one particular value, and/or 25 to "about" another particular value. When such a range is expressed, another aspect includes from the one particular value and/or to the other particular value. Similarly,

when values are expressed as approximations, by use of the antecedent "about," it will be understood that the particular value forms another aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint, and independently of the other endpoint.

5 Provided herein are compositions and methods designed to reduce or prevent bacterial infections (for example pneumococcal infections), nasal carriage, nasal colonization, and CNS invasion. *S. pneumoniae* colonizes the nasal tract in part by crossing the epithelial barrier through C-polysaccharide-ganglioside interactions with subsequent endocytosis into epithelial cells. C-polysaccharide binds to asialo-GM1, 10 asialo-GM2, and fucosyl-asialo-GM1 through binding to a terminal or internal GalNAc β 1-4Gal sequence in the ganglioside. Although the abundance of these asialogangliosides in the plasma membrane of cells is normally low, with the exception of the human lungs *S. pneumoniae* has two neuraminidases, NanA and NanB (Berry et al., (1996) *J. Bacteriol.* 178: 4854-4860), which can each cleave α 2,3- 15 and α 2,6- linkages of N-acetylneuraminic acid to galactose, and α 2,6-linkage to N-acetyl-galactosamine. Scanlon et al., (1989) *Enzyme* 41: 143-150. Sialic acid residues on gangliosides are α 2,3 linked to galactose. Neuraminidases of *S. pneumoniae* remove end-terminal sialic acid residues, which are present on all 20 monosialogangliosides, and galactose-linked multiple sialic acid residues, as seen in the di- and trisialogangliosides. Thus, they should be able to expose the GalNAc β 1-4Gal sequence found in the most common mammalian cell surface gangliosides. These residues are the presumed C-polysaccharide binding site on the cell surface. 25 Using its NanA, which is normally more cell wall associated, and NanB, which is thought to be secreted, *S. pneumoniae* generates its own attachment sites on epithelial cells in the respiratory tract. Thus, pneumococcal C-polysaccharide binds to asialogangliosides, in particular asialo-GM1, and the neuraminidases, which can convert the rather abundant GM1 into asialo-GM1, may create abundant binding sites on ON/E for the C-polysaccharide. This mechanism facilitates nasal carriage and provides access for *S. pneumoniae* to the CNS through the nasal olfactory nerves and

epithelium covering the nasal turbinates (ON/E), olfactory bulbs (OB). Similarly, otitis media and other infections involving *S. pneumoniae* can similarly gain access to the CNS through nerves innervating the middle ear. Other bacteria in addition to *S. pneumoniae* have comparable neuraminidases, thus the same mechanism occurs in 5 other bacteria as well. Thus disclosed herein are compositions and methods targeting this mechanism in a variety of bacteria. The agents, compositions, and methods taught herein are directed to interrupting this mechanism to reduce carriage and to prevent CNS invasion.

10 Optionally, the compositions are designed for mucosal administration. For example, provided herein is a composition comprising a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface. Optionally, the composition can comprise any combination of a 15 pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these.

20 Optionally, the composition is in the form of an aerosol, nasal mist, nasal spray, nasal drops, a nebulizer solution, an aerosol inhalant, a suppository, or any form appropriate for mucosal administration (including oral administration). Optionally, the compositions can be in microspheres or in liposomes for delivery. By 25 "administration to a mucosal surface" is meant administration to any mucosal surface including the respiratory system, the gastrointestinal system, or the urogenital system. Examples of mucosal surfaces include but are not limited to the nasal cavity (including to the olfactory neuroepithelium), the nasopharynx, the rectum, the vagina, the larynx, the mouth, the Eustachian tube, the trachea, the bronchi and other airways, and the intestinal mucosa.

For administration to a mucosal surface a mucosal adjuvant can be used. The adjuvant can administered concomitantly with the composition of the invention, immediately prior to, or after administration of the composition. Optionally, the composition further comprises the adjuvant. Mucosal adjuvant formulations include,

5 for example, an agent that targets mucosal inductive sites. The adjuvant may optionally be selected from the group including, but not limited to, cytokines, chemokines, growth factors, angiogenic factors, apoptosis inhibitors, and combinations thereof. When a cytokine is chosen as an adjuvant, the cytokine may be selected from the group including, but not limited to, interleukins including IL-1, IL-10 1[agr], IL-1[bgr], IL-2, IL-5, IL-6, IL- 12, IL-15 and IL-18; transforming growth factor-beta (TGF[bgr]); granulocyte macrophage colony stimulating factor (GM-CSF); interferon- gamma (IFN[agr]); or other cytokine which has adjuvant activity. Portions of cytokines, or mutants or mimics of cytokines (or combinations thereof), having adjuvant activity or other biological activity can also be used in the compositions and

15 methods of the present invention.

When a chemokine is chosen as an adjuvant, the chemokine may optionally be selected from a group including, but not limited to, Lymphotactin, RANTES, LARC, PARC, MDC, TARC, SLC and FKN. When an apoptosis inhibitor is chosen as an adjuvant, the apoptosis inhibitor may optionally be selected from the group including, 20 but not limited to, inhibitors of caspase-8, and combinations thereof. When an angiogenic factor is chosen as an adjuvant, the angiogenic factor may optionally be selected from the group including, but not limited to, a basic fibroblast growth factor (FGF), a vascular endothelial growth factor (VEGF), a hyaluronan (HA) fragment, and combinations thereof. Indeed, plus (+) and minus(-) angiogenic factors may be chosen 25 as adjuvants.

Other examples of substantially non-toxic, biologically active mucosal adjuvants of the present invention include hormones, enzymes, growth factors, or biologically active portions thereof. Such hormones, enzymes, growth factors, or

biologically active portions thereof can be of human, bovine, porcine, ovine, canine, feline, equine, or avian origin, for example, and can be tumor necrosis factor (TNF), prolactin, epidermal growth factor (EGF), granulocyte colony stimulating factor (GCSF), insulin-like growth factor (IGF-1), somatotropin (growth hormone) or 5 insulin, or any other hormone or growth factor whose receptor is expressed on cells of the immune system.

10 Adjuvants for mucosal administration also include bacterial toxins, e.g., the cholera toxin (CT), the *E. coli* heat-labile toxin (LT), the Clostridium difficile toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, chimera, or mutants thereof. For example, a purified preparation of native cholera toxin subunit B (CTB) can be used. Fragments, homologs, derivatives, and fusions to any of these toxins are also suitable, provided that they retain adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants are described, e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-15 Lys and Glu-129-Gly PT mutant). Additional LT mutants that can be used in the methods and compositions of the invention include, e.g., Ser-63-Lys, Ala- 69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants, such as RH3-ligand; CpG-motif oligonucleotide; a bacterial monophosphoryl lipid A (MPLA) of, e.g., *E. coli*, *Salmonella minnesota*, *Salmonella typhimurium*, or *Shigella flexneri*; saponins (e.g., 20 QS21), or polylactide glycolide (PLGA) microspheres, can also be used in mucosal administration. Possible other mucosal adjuvants are defensins and CpG motifs containing oligonucleotides.

25 As used throughout, a "pharmaceutically acceptable carrier" is meant as a material that is not biologically or otherwise undesirable, i.e., the material can be administered to an individual along with the selected compound without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

Any of the compositions described herein can be used therapeutically with a pharmaceutically acceptable carrier. The compounds described herein can be conveniently formulated into pharmaceutical compositions composed of one or more of the compounds in association with a pharmaceutically acceptable carrier. See, e.g.,

5 5 *Remington's Pharmaceutical Sciences*, latest edition, by E.W. Martin Mack Pub. Co., Easton, PA, which discloses typical carriers and conventional methods of preparing pharmaceutical compositions that can be used in conjunction with the preparation of formulations of the compounds described herein and which is incorporated by reference herein. These most typically would be standard carriers for administration

10 10 of compositions to humans. In one aspect, humans and non-humans, including solutions such as sterile water, saline, and buffered solutions at physiological pH. Other compounds will be administered according to standard procedures used by those skilled in the art.

The pharmaceutical compositions described herein can include, but are not limited to, carriers, thickeners, diluents, buffers, preservatives, surface active agents and the like in addition to the molecule of choice. Pharmaceutical compositions can also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.

By a pneumococcal neuraminidase is meant any neuraminidase molecule found in pneumococcal bacteria. Table 1 shows the alignment of neuraminidases from several species. As identified throughout, the amino acid residues for all amino acid sequences are numbered in accordance with the amino acid sequence of pneumococcal strain R6 as shown in Table 1.

Any antigenic variant of neuraminidase could also be used in the compositions or methods taught herein. Thus, the naturally occurring neuraminidase can be modified by substitution, deletion, or alteration of amino acid residues in accordance with the methods taught herein. Optionally, such modifications will be designed to

detoxify the neuraminidase. By "detoxification" is meant a reduction or elimination in enzymatic activity, while maintaining antigenicity or immunogenicity. This is accomplished by substitution, deletion, or alteration of amino acids in the active site of the neuraminidase using site specific mutagenesis. Preferably, such substitutions, 5 deletions, or alterations will be within the Asp boxes (i.e., within amino acid residues 460-480, 530-560, or 600-620). See Crennell et al., PNAS 90:9852-9856, which is incorporated herein by reference in its entirety for the neuraminidase structure taught therein. Alterations in the Asp boxes can include replacement of aspartic acid with glutamic acid or threonine. Other conservative or non-conservative amino acid 10 replacements can also be used at the aspartic acid residue or any other residue in the Asp boxes to reduce toxicity. Other regions of the neuraminidase are optionally targeted for site specific mutagenesis. For example, modifications within the region corresponding to residues 570-580, including for example conservative and non-conservative amino acid substitutions of valine or glutamine at position 575 are 15 disclosed. Also disclosed are neuraminidases with modifications in the regions corresponding to residues 750-760, and more specifically the tyrosine at position 754. Conservative amino acid substitutions for the tyrosine residue include, for example, serine or threonine. Also provided are neuraminidases with modifications in the regions corresponding to amino acid residues 340-350, 600-610, or 360-370. More 20 specifically, the arginines at positions 347, 605, or 366 can be substituted with lysine or glutamine, or any other conservative or non-conservative amino acids. The various modifications taught herein can be used in combination. Thus, one or more conservative or non-conservative amino acid substitutions are optionally present in the same neuraminidase.

25 Other conservative and non-conservative substitutions in neuramindase may be used so long as the neuraminidase maintains its antigenicity or immunogenicity. These conservative substitutions are such that a naturally occurring amino acid is replaced by one having similar properties. Such conservative and nonconservative substitutions

optionally alter the enzymatic function of the polypeptide. For example, conservative substitutions can be made according to Table 2.

TABLE 2: Amino Acid Substitutions	
Original Residue	Exemplary Substitutions
Arg	Lys
Asn	Gln
Asp	Glu
Cys	Ser
Gln	Asn
Glu	Asp
Gly	Pro
His	Gln
Ile	<u>leu; val</u>
Leu	<u>ile; val</u>
Lys	arg; gln
Met	leu; ile
Phe	met; leu; tyr
Ser	Thr
Thr	Ser

Trp	Tyr
Tyr	trp; phe
Val	ile; leu

It is understood that, where desired, modifications and changes may be made in the nucleic acid encoding the polypeptides of this invention and/or amino acid sequence of the polypeptides of the present invention and still obtain a polypeptide having like or otherwise desirable characteristics (e.g., antigenicity or immunogenicity). Such changes may occur in natural isolates or may be synthetically introduced using site-specific mutagenesis, the procedures, such as miss-match polymerase chain reaction (PCR), are well known in the art. For example, certain amino acids may be substituted for other amino acids in a polypeptide without appreciable loss of functional activity. It is thus contemplated that various changes may be made in the amino acid sequence of the polypeptides of the present invention (or underlying nucleic acid sequence) without appreciable loss of biological utility or activity and possibly with an increase in such utility or activity.

Deletions of the *nanA* gene or any portion of the *nanA* gene are carried out using the method described by Sung et al., (2001) *Appl Environ Microbiol* 67: 5190-5196, which is incorporated herein by reference in its entirety for the methods taught therein. The reagent 2, 3 butadione, which specifically reacts with Arg residues of proteins, is used to assess the importance of Arg residues to the folding of the NanA molecule. Site-directed mutagenesis is used to alter specific amino-acids.

The neuraminidase can also be detoxified by chemical treatment, including for example denaturation. Chemical treatment can also be combined with site-specific mutagenesis to further reduce negative side effects and improving antigenicity or immunogenicity.

Thus provided herein is a detoxified pneumococcal neuraminidase or an antigenic or immunogenic fragment thereof. Also provided are compositions comprising the detoxified pneumococcal neuraminidase and a pharmaceutically acceptable carrier. Optionally the composition further comprises an adjuvant

5 (including, for example, a mucosal adjuvant).

Furthermore, moieties can be added to the neuraminidase, including, for example, moieties that increase antigenicity or immunogenicity. Such moieties include, for example, cytokines, chemokines, growth factors, angiogenic factors, apoptosis inhibitors, hormones, toxins, or other moieties discussed herein for use as 10 adjuvants. The moieties can optionally be modified or truncated for use in the altered molecules. Thus provided herein is a pneumococcal neuraminidase chimera comprising the neuraminidase or an antigenic or immunogenic fragment thereof and a moiety that enhances antigenicity or immunogenicity. Also provided are compositions comprising the pneumococcal neuraminidase derivatives and a 15 pharmaceutically acceptable carrier. Optionally the composition further comprises an adjuvant (including, for example, a mucosal adjuvant).

Optionally the modified neuraminidase or fragment thereof of the invention has an amino acid sequence with at least about 70% homology with a naturally occurring pneumococcal neuraminidase or fragment thereof. Further provided are 20 nucleic acids that encode the modified neuraminidases or fragments thereof. It is understood that one way to define any known variants and derivatives or those that might arise, of the disclosed nucleic acids and proteins herein is through defining the variants and derivatives in terms of homology to specific known sequences. For example, the amino acid sequence encoded by the nana gene of the R6 pneumococcal 25 strain as shown in Table 1 sets forth a particular sequence of a pneumococcal neuraminidase and sets forth a particular amino acid sequence of the protein. Specifically disclosed are variants of this sequence herein disclosed which have at least, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,

91, 92, 93, 94, 95, 96, 97, 98, 99 percent homology to the stated sequence. Those of skill in the art readily understand how to determine the homology of two proteins or nucleic acids. For example, the homology can be calculated after aligning the two sequences so that the homology is at its highest level.

5 Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by the homology alignment algorithm of Needleman and Wunsch, *J. Mol. Biol.* 48: 443 (1970), by the search for similarity method of Pearson and Lipman, *Proc. Natl. Acad. Sci. U.S.A.* 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by inspection. The same types of homology can be obtained for nucleic acids by for example the algorithms disclosed in Zuker, M. *Science* 244:48-52, 1989, Jaeger et al. *Proc. Natl. Acad. Sci. USA* 86:7706-7710, 1989, Jaeger et al. *Methods Enzymol.* 183:281-306, 1989 which are herein incorporated by reference for at least material related to nucleic acid alignment.

20 By "a pneumococcal phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid" is meant a phosphocholine, a teichoic acid, or a lipoteichoic acid present in pneumococcal bacteria. These compounds can be modified, detoxified, or enhanced as described above for the neuraminidase. Provided herein are compositions comprising the modified, detoxified, and enhanced compounds.

25 By "an antigenic portion thereof" is meant any epitope of a molecule or compound (e.g., neuraminidase, phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid) that elicits antibody production, wherein the antibody is directed to the molecule. Preferably, the antigenic portion elicits immunity to the

molecule or to *S. pneumoniae*. Preferably the antibodies are directed to or interfere with active sites of the neuraminidase. Examples of antigenic fragments include, but are not limited to, residues corresponding to residues 63-361 of the nana-R6 amino acid sequence, in the presence or absence of conservative amino acid substitutions or modifications. Other examples include the Asp regions of neuraminidase (corresponding to residues 460-480, 530-560, 610-620 of the NanA-R6 amino acid sequence) and regions corresponding to 340-350, 360-370, 600-610, 570-580 and 750-760 of the NanA-R6 amino acid sequence, in the presence or absence of conservative amino acid substitutions or modifications. Other examples of NanA fragments include amino acids 1 to 340, 330 to 630, 620 to 800, 700 to 1030 and 330 to 800. Further provided are fragments that are fusions of two or more of these fragments. Fused fragments include, but are not limited to, regions 1 to 340 fused with regions 620-680. Fused fragments are expressed as a recombinant protein. Fragments that encode these fragments are cloned into an expression vector (pET Vectors; Novagen, Inc.) and the protein is purified. Alternatively, fragments are generated as a synthetic polypeptide from a vendor. Fragments are used to immunize animals to generate antibodies and to crystallize in order to assess three-dimensional structures. Further provided are nucleic acids encoding the fragments in the presence or absence of conservative or non-conservative amino acid modifications, or substitutions, as described herein. Also provided are vectors or expression systems comprising the nucleic acids.

Provided herein are compositions comprising isolated antibodies that specifically bind pneumococcal neuraminidase, phosphocholine, teichoic acid, lipoteichoic acid, or an antigenic portion of one or both of these. Also provided is a composition comprising any combination of the antibodies. Such antibodies are useful in developing passive immunity to *S. pneumoniae*. The antibody compositions further comprise a pharmaceutically acceptable carrier. Optionally, the composition is suitable for administration to a mucosal surface, but other routes of administration are disclosed, including systemic administration as described herein.

Also disclosed herein are methods of generating antibodies specific to pneumococcal neuraminidase, phosphocholine, teichoic acid, lipoteichoic acid, or any epitope of pneumococcal neuraminidase, phosphocholine, teichoic acid, or lipoteichoic acid. Optionally, the antibodies are generated in a subject (i.e., *in vivo*) by

5 contacting the nasal mucosa of the subject with an effective amount of a composition disclosed herein. Also, disclosed is a method of generating antibodies specific to any combination of pneumococcal neuraminidase, phosphocholine, teichoic acid, lipoteichoic acid, or any epitope of pneumococcal neuraminidase, phosphocholine, teichoic acid, or lipoteichoic acid by contacting the nasal mucosa of the subject with

10 an effective amount of a composition comprising a combination of target molecules or antibodies that target the molecules.

Optionally, the agents described herein, whether naturally occurring, detoxified or otherwise modified, can optionally be administered as a nucleic acid, for example, within a vector. Expression of the nucleic acid would then result in

15 contacting the subject with the desired nucleic acid expressed thereby. Thus, for example, if a nucleic acid encoding pneumococcal neuraminidase is administered to a subject in a form that can be expressed within the subject, then the subject is contacted with the neuraminidase.

In the methods described herein which include the administration and uptake

20 of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the disclosed nucleic acids can be in the form of naked DNA or RNA, or the nucleic acids can be in a vector for delivering the nucleic acids to the cells, whereby the antibody-encoding DNA fragment is under the transcriptional regulation of a promoter, as would be well understood by one of ordinary skill in the art. The vector

25 can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN,

LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the disclosed nucleic acid or vector can be delivered *in vivo* by gene gun or other delivery methods such as electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., Proc. Natl. Acad. Sci. U.S.A. 85:4486, 1988; Miller et al., Mol. Cell. Biol. 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells nucleic acid encoding for example pneumococcal neuraminidase or a broadly neutralizing antibody (or active fragment thereof). The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of adenoviral vectors (Mitani et al., Hum. Gene Ther. 5:941-948, 1994), adeno-associated viral (AAV) vectors (Goodman et al., Blood 84:1492-1500, 1994), lentiviral vectors (Naidini et al., Science 272:263-267, 1996), pseudotyped retroviral vectors (Agrawal et al., Exper. Hematol. 24:738-747, 1996). Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzenberger et al., Blood 87:472-478, 1996). This disclosed compositions and methods can be used in conjunction with any of these or other commonly used gene transfer methods.

As one example, if the antibody-encoding nucleic acid is delivered to the cells of a subject in an adenovirus vector, the dosage for administration of adenovirus to humans can range from about 10^7 to 10^9 plaque forming units (pfu) per injection but can be as high as 10^{12} pfu per injection (Crystal, Hum. Gene Ther. 8:985-1001, 1997; Alvarez and Curiel, Hum. Gene Ther. 8:597-613, 1997). A subject can receive a

single injection, or, if additional injections are necessary, they can be repeated at six month intervals (or other appropriate time intervals, as determined by the skilled practitioner) for an indefinite period and/or until the efficacy of the treatment has been established.

5 Parenteral administration of the nucleic acid or vector, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system

10 such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein. For additional discussion of suitable formulations and various routes of administration of therapeutic compounds, see, e.g., Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.

15 Also disclosed is a method of reducing or preventing pneumococcal nasal carriage in a subject comprising contact of the nasal mucosa of the subject with an effective amount of a composition disclosed herein. Such administration can be useful in generating active or passive immunity to or protection against pneumococcal infection or nasal carriage.

20 Further provided is a method of reducing or preventing pneumococcal infection in a subject comprising contact of a mucosal surface of the subject with an effective amount of a composition disclosed herein. For example, the method can prevent pneumococcal meningitis, otitis media, pneumonia, or hemolytic uremia. Prevention or reduction can occur by reducing nasal carriage and or preventing CNS

25 invasion, systemic invasion, or invasion of the Eustachian tubes or lower airways.

By the term "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound to provide the desired result. As will

be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount."

5 However, an appropriate effective amount can be determined by one of ordinary skill in the art using only routine experimentation.

The dosages or amounts of the compositions described herein are large enough to produce the desired effect in the method by which delivery occurs. The dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like. Generally, the dosage will vary with the age, condition, sex and extent of the disease in the subject and can be determined by one of skill in the art. The dosage can be adjusted by the individual physician based on the clinical condition of the subject involved. The dose, schedule of doses and route of administration can be varied. Preferred dosages include for nasal applications of antigen between about 1-1000 μ g per immunization or any amount in between, including for example 10-100 μ g.

The efficacy of administration of a particular dose of the compounds or compositions according to the methods described herein can be determined by evaluating the particular aspects of the medical history, signs, symptoms, and objective laboratory tests that are known to be useful in evaluating the status of a subject with pneumococcal infection or who is a pneumococcal carrier. These signs, symptoms, and objective laboratory tests will vary, depending upon the particular disease or condition being treated or prevented, as will be known to any clinician who treats such patients or a researcher conducting experimentation in this field. For example, if, based on a comparison with an appropriate control group and/or knowledge of the normal progression of the disease in the general population or the particular individual: 1) a subject's physical condition is shown to be improved (e.g., nasal carriage is reduced or eliminated), 2) the progression of the disease, infection, or

nasal carriage is shown to be stabilized, slowed, or reversed, or 3) the need for other medications for treating the disease or condition is lessened or obviated, then a particular treatment regimen will be considered efficacious. For example, reducing or preventing nasal carriage in a subject or in a population, avoiding or reducing the occurrence of CNS invasion or other secondary pneumococcal infections would indicate efficacy. Such effects could be determined in a single subject (e.g., by reducing the number of bacteria detected with a traditional swab of the mucosal surface) or in a population (e.g., using epidemiological studies).

The compounds and pharmaceutical compositions described herein can be administered to the subject in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Thus, for example, a compound or pharmaceutical composition described herein can be administered intravenously, subcutaneously, intramuscularly, encapsulated in liposomes or microspheres, as an ophthalmic solution and/or ointment to the surface of the eye, as a nasal spray, as a nebulized solution, or as an aerosol to the nasal cavities or airways. Moreover, a compound or pharmaceutical composition can be administered to a subject vaginally, rectally, intranasally, orally, by inhalation, orally, or by intubation. Optionally, the composition is administered by intravenous, subcutaneous, intramuscular, or intraperitoneal injection. The composition can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid, or as emulsions. Optionally, administration is by slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein for the methods taught therein.

The compositions taught herein include sterile aqueous or non-aqueous solutions, suspensions, and emulsions which can also contain buffers, diluents and other suitable additives. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and organic esters such as ethyl

oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Preservatives and other additives can also be present such as, for example, 5 antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

Formulations for local administration can include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, aerosols, nebulizer solutions and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable.

10 Compositions for oral administration can include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders can be desirable.

15 Provided herein are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to a subject an effective amount of a neuraminidase inhibitor. Preferably, the neuraminidase inhibitor inhibits pneumococcal neuraminidase activity without significantly reducing the subject's endogenous neuraminidase. Thus, for example, if the neuraminidase is administered to a human, the inhibitor will preferably inhibit pneumococcal neuraminidase without 20 reducing the human neuraminidase activity, or without reducing human neuraminidase activity such that negative side-effects results in the human. Examples of known neuraminidase inhibitors include DANA, NANA, zanamivir and oseltamivir.

25 Provided herein is a method of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to a subject an effective amount of a composition comprising antibodies against pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or antibodies against a portion of any one of these. Optionally this

administration comprises contacting a mucosal surface of the subject with the composition.

The term "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. Chimeric antibodies, and hybrid antibodies, 5 with dual or multiple antigen or epitope specificities, and fragments, such as F(ab')2, Fab', Fab, scFv, and the like, including hybrid fragments can also be used in the compositions and methods described herein. Thus, fragments of the antibodies that retain the ability to bind their specific antigens are provided. For example, fragments of antibodies which maintain neuraminidase, phosphocholine, teichoic acid, or 10 lipoteichoic acid binding activity are included within the meaning of the term "antibody fragment." Such antibodies and fragments can be made by techniques known in the art and can be screened for specificity and activity according to the methods set forth in the Examples and in general methods for producing antibodies and screening antibodies for specificity and activity (See Harlow and Lane. 15 Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988)).

Conjugates of antibody fragments and antigen binding proteins (single chain antibodies) can be used in the composition of the invention. Such conjugates are described, for example, in U.S. Pat. No. 4,704,692, the contents of which are hereby 20 incorporated by reference. The antibodies can be tested for their desired activity using *in vitro* assays, or by analogous methods, after which their *in vivo* therapeutic and/or prophylactic activities are tested according to known clinical testing methods.

The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual 25 antibodies within the population are identical except for possible naturally occurring mutations that may be present in a small subset of the antibody molecules. The disclosed monoclonal antibodies can be made using any procedure which produces

monoclonal antibodies. For example, disclosed monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, *Nature*, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that 5 produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*, e.g., using the HIV Env-CD4-co-receptor complexes described herein.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567 (Cabilly et al.). DNA encoding the 10 disclosed monoclonal antibodies can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). Libraries of antibodies or active antibody fragments can also be generated and screened using phage display techniques, e.g., as described in U.S. 15 Patent No. 5,804,440 to Burton et al. and U.S. Patent No. 6,096,441 to Barbas et al.

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 20 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross linking antigen.

25 The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the

antibody or antibody fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any 5 case, the antibody or antibody fragment must possess a bioactive property, such as specific binding to its cognate antigen. Functional or active regions of the antibody or antibody fragment may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site- 10 specific mutagenesis of the nucleic acid encoding the antibody or antibody fragment. (Zoller, M.J. Curr. Opin. Biotechnol. 3:348-354, 1992).

As used herein, the term "antibody" or "antibodies" can also refer to a human antibody and/or a humanized antibody. Many non-human antibodies (e.g., those derived from mice, rats, or rabbits) are naturally antigenic in humans, and thus can 15 give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response. Thus, the compositions comprising antibodies optionally comprise humanized or 20 fully human antibodies. Antibody humanization techniques generally involve the use of recombinant DNA technology to manipulate the DNA sequence encoding one or more polypeptide chains of an antibody molecule. Accordingly, a humanized form of a non human antibody (or a fragment thereof) is a chimeric antibody or antibody chain (or a fragment thereof, such as an Fv, Fab, Fab', or other antigen binding portion of an antibody) which contains a portion of an antigen binding site from a non-human 25 (donor) antibody integrated into the framework of a human (recipient) antibody.

The disclosed human antibodies can be prepared using any technique. Examples of techniques for human monoclonal antibody production include those described by Cole et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p.

77, 1985) and by Boerner et al. (J. Immunol., 147(1):86 95, 1991). Human antibodies (and fragments thereof) can also be produced using phage display libraries (Hoogenboom et al., J. Mol. Biol., 227:381, 1991; Marks et al., J. Mol. Biol., 222:581, 1991).

5 The disclosed human antibodies can also be obtained from transgenic animals. For example, transgenic, mutant mice that are capable of producing a full repertoire of human antibodies, in response to immunization, have been described (see, e.g., Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 255 (1993); Jakobovits et al., Nature, 362:255 258 (1993); Brugermann et al., Year in Immunol., 7:33 (1993)).

10 Specifically, the homozygous deletion of the antibody heavy chain joining region (J(H)) gene in these chimeric and germ line mutant mice results in complete inhibition of endogenous antibody production, and the successful transfer of the human germ line antibody gene array into such germ line mutant mice results in the production of human antibodies upon antigen challenge. Antibodies having the desired activity are

15 selected using Env-CD4-co-receptor complexes as described herein.

 To generate a humanized antibody, residues from one or more complementarity determining regions (CDRs) of a recipient (human) antibody molecule are replaced by residues from one or more CDRs of a donor (non human) antibody molecule that is known to have desired antigen binding characteristics (e.g., 20 a certain level of specificity and affinity for the target antigen). In some instances, Fv framework (FR) residues of the human antibody are replaced by corresponding non human residues. Humanized antibodies may also contain residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. Generally, a humanized antibody has one or more amino acid residues introduced into 25 it from a source which is non human. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. Humanized antibodies generally contain at least a portion of an antibody constant region (Fc),

typically that of a human antibody (Jones et al., *Nature*, 321:522 525 (1986), Reichmann et al., *Nature*, 332:323 327 (1988), and Presta, *Curr. Opin. Struct. Biol.*, 2:593 596 (1992)).

Methods for humanizing non human antibodies are well known in the art. For 5 example, humanized antibodies can be generated according to the methods of Winter and co workers (Jones et al., *Nature*, 321:522 525 (1986), Riechmann et al., *Nature*, 332:323 327 (1988), Verhoeyen et al., *Science*, 239:1534 1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Methods that can be used to produce humanized antibodies are also 10 described in U.S. Patent No. 4,816,567 (Cabilly et al.), U.S. Patent No. 5,565,332 (Hoogenboom et al.), U.S. Patent No. 5,721,367 (Kay et al.), U.S. Patent No. 5,837,243 (Deo et al.), U.S. Patent No. 5, 939,598 (Kucherlapati et al.), U.S. Patent No. 6,130,364 (Jakobovits et al.), and U.S. Patent No. 6,180,377 (Morgan et al.).

Administration of the antibodies can be done as disclosed herein. Nucleic acid 15 approaches for antibody delivery also exist. The antibodies and antibody fragments can also be administered to patients or subjects as a nucleic acid preparation (e.g., DNA or RNA) that encodes the antibody or antibody fragment, such that the subject's own cells take up the nucleic acid and produce and secrete the encoded antibody or antibody fragment. The delivery of the nucleic acid can be by any means known in 20 the art.

Also disclosed herein are containers comprising the agents and compositions taught herein. Specifically, the container can be a nasal sprayer, a nebulizer, an inhaler, a bottle, or any other means of containing the composition in a form for administration to a mucosal surface. Optionally, the container can deliver a metered 25 dose of the composition.

EXAMPLES

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and/or methods described and claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, temperature is in °C or is at ambient temperature, and pressure is at or near atmospheric. There are numerous variations and combinations of reaction conditions, e.g., component concentrations, desired solvents, solvent mixtures, temperatures, pressures and other reaction ranges and conditions that can be used to optimize the product purity and yield obtained from the described process. Only reasonable and routine experimentation will be required to optimize such process conditions.

Example 1

Nasal Pneumococci Penetrate Olfactory Tissues During Carriage

20 **Materials And Methods**
Pneumococcal Strains

The studies employed two encapsulated strains of *S. pneumoniae* EF3030, serotype 19F, and TIGR4 strain, serotype 4 and the avirulent, non-capsular strain R36A derived from the parent strain D39, serotype 2. Avery et al., (1944) J. Exp. Med. 79: 137-158. The EF3030 strain was chosen since it readily colonizes the respiratory tract in the absence of bacteremia (Briles et al., (1992) Infect. Immun. 60: 111-116) and is incapable of sustained bacteremia following intravenous inoculation. The TIGR4 strain was more virulent, but with a modest nasal inoculum colonizes without bacteremia.

Mice

The CRA/CAHN/*xid* (*xid*) mouse strain was obtained from the Jackson Laboratory (Bar Harbor, ME). The mutation in the Bruton's tyrosine kinase gene of these mice results in an inability to respond to thymus-independent type II antigens 5 (Amsbaugh et al., (1972) J. Exp. Med. 136: 931-949; Berning et al., (1980) J. Immunol. 46: 506-513), but permits relatively normal T cell-dependent immune responses. These mice fail to respond to capsular polysaccharides and are reproducibly susceptible to pneumococcal infection. The *xid* mice were maintained under pathogen-free conditions and were used at 7-12 weeks of age.

10 Tissue Collection

The blood was collected into a heparinized capillary tube from the retroorbital plexus. Mice were disinfected with 70 % ethanol prior to collection of nasal wash (NW), kidney, spleen, and lungs. To prevent blood contamination of the NW an incision was made into the trachea and a 2.0 cm long Tygon tube with an outer 15 diameter of 0.075 cm (Cole-Parmer, Vernon Hills, IL) was inserted into the nasopharynx while attached to a syringe filled with Ringer's solution. Fluid from the syringe was expelled through the nose and three drops were collected.

The nasopharyngeal-associated lymphoreticular tissue (NALT), ON/E, OBs and remainder of the brain were obtained as described. van Ginkel et al., (2000) J. 20 Immunol. 165: 4778-4782; Wu et al., (1997) Scand. J. Immunol 46: 506-513. The trigeminal ganglia were carefully excised from the brain with a dissection microscope. The ON/E, OBs, trigeminal ganglia, NALT and cervical lymph nodes CLNs were each homogenized in 0.5 ml Ringer's solution and the brain and kidney each homogenized in 1.0 ml of Ringer's solution.

Quantity of Pneumococci In Tissue Minces / Blood / External Excretions

Eight serial, three-fold dilutions were made of tissues and body fluids in sterile Ringer's solution and plated on blood agar plates containing 4 µg/ml of gentamicin sulfate. The CFU were enumerated 24 hr after plating and incubation in a candle jar.

5 The results were expressed as CFUs/organ, per NW or per ml of blood.

GLS Preincubation of *S. pneumoniae* Strain EF3030

To block GLS binding sites, 3 X 10⁷ CFU of *S. pneumoniae* strain EF3030 were incubated for 30 min on ice with either 20 µg asialo-GM1 from human brain or 125 µg of mixed GLSs (18% GM1, 55% GD1a, 15% GD1b, 10% GT1b, 2% other GLSs) from bovine brain (Calbiochem-Novabiochem Corporation, Inc., La Jolla, CA). GLSs were dissolved in PBS and extensively mixed a day prior to use. The amphiphilic GLSs formed micelles in PBS allowing interaction of pneumococci with the carbohydrate moiety. Following incubation, 5 µl per nare was applied nasally to *xid* mice without further washing. Tissues were analyzed for CFUs four days later.

15 Detection of *S. pneumoniae* Pneumolysin Gene By PCR

To detect *S. pneumoniae* by PCR, tissues were lysed in 1% SDS with 0.1% deoxycholic acid by freeze-thawing, and incubated at 37° C for 1 hr. Proteins were removed using the cetyltrimethylammoniumbromide/NaCl precipitation method (Ausubel et al., (1987) Current Protocols in Molecular Biology, 2nd: 2.4.4, which is incorporated herein by reference for teaching of the cetyltrimethylammoniumbromide/NaCl precipitation method). Ten µg of DNA was used for PCR amplification. The pneumolysin(ply)-specific primers Ply1 5'-ATTTCTGTAACAGCTACCAACGA-3' (SEQ ID NO:1) and Ply2 5'-GAATTCCCTGTCTTTCAAAGTC-3' (SEQ ID NO:2) were added to the PCR mixture to amplify a 400 bp fragment. The PCR reaction involved a 5 min denaturation step at 94° C followed by the amplification cycle: 94° C (1 min), 55° C

(1 min), and 72° C (1 min) for 30 cycles. Images of the ethidium bromide stained PCR fragments were collected on an Alpha Imager TM IS-3400 (Alpha Innotech Corporation, San Leandro, CA).

Immunofluorescent Staining Of OBs With PspA-specific Abs

5 Mice were nasally challenged with 5×10^5 CFU of the TIGR4 strain. The OBs were fixed in 10 % buffered formalin. Four μ m paraffin sections (van Ginkel (2000) J. Immunol. 165: 4778-4782) were stained for PspA family 2 Abs (1:100) by incubating them for 4 hr at room temperature in a humidified chamber. Slides were washed in PBS, stained with biotinylated goat F(ab')2 anti-rabbit IgG (1:200)
10 (Southern Biotechnology Associates, Inc., Birmingham, AL), washed and stained with streptavidin-FITC (1:100) (BD-PharMingen, San Diego, CA). Fluorescent images were collected with a Nikon microscope using a DEI-750 CE digital color video camera (Optronics, Goleta, CA) and processed with the Scion Image software (Scion Corporation, Frederick, MD).

15 Statistics

The data are expressed as the mean \pm one standard error and the results were compared by statistical analysis to determine significant differences in CFUs using the unpaired Mann Whitney two sample rank test or student t-test.

Results

20 The Role of the Pneumococcal Capsule in Nasal Colonization and CNS Invasion

To examine the up-take of pneumococci through primary sensory olfactory neurons, the ability of EF3030 and a non-encapsulated strain R36A to colonize the nasal tract and enter the CNS were measured at days 1 and 4 (Fig. 1). Although high CFU for both strains were observed in the ON/E on day 1, the R36A were largely absent by day 4 from the ON/E and all other tissues, consistent with earlier results
25

indicating that some capsule is required for prolonged colonization. Magee and Yother (2001) Infect. Immun. 69: 3755-3761. EF3030 showed a clear presence in the OB and brain on both days and were present in high numbers in the NWs and NALT on day 4. These findings were consistent with axonal transport of EF3030 pneumococci into the OBs and brain after nasal challenge.

5

Kinetics of Nasal Colonization and CNS Invasion

EF3030 was maintained in the ON/E, OBs, NWs, and NALT at all time points over the 39 days of observation (Fig. 2). Much lower numbers of CFU were seen in the brain and CLN, and those CFU present were generally seen at 18 and 25 days.

10 Interestingly, the lungs did not exhibit pneumococci except at day 1 (Fig. 1) and at days 18, 25 and 39 (Fig. 2). Bacteremia did not contribute to the neuronal tissue distribution, since no CFU were detected in the bloodstream of mice during any of the experiments performed with strain EF3030 at the nasal dose used (Fig. 2). Blood was monitored for bacteremia at 1, 3, 6, 12 and 24 hr after nasal application and every

15 subsequent day for one week. No bacteria were detected in the blood.

15

S. pneumoniae Infection of Trigeminal Ganglia

The trigeminal neurons innervate the nasopharynx and thus, *S. pneumoniae* would be expected in the trigeminal ganglia after infection of the nasal mucosa. To test this, various tissues and blood were isolated four days after inoculation and

20 analyzed for the presence of EF3030 in new experiments. The EF3030 strain was detected in ON/E and OBs and in trigeminal ganglia (Table 3). This finding further supported that asialo-GM1 function as receptors for neuronal targeting by *S. pneumoniae*. Other GLSs likely play a role as well.

20

Table 3 shows the distribution of *S. pneumoniae* strain EF3030 in various tissues after nasal delivery. Tissues were isolated on day 4 after nasal application of 1 x 10⁷ CFUs of strain EF3030. Blood (50 µl), ON/E, OBs, and brain tissue minces

25

were diluted and then plated on blood agar. The trigeminal ganglia were pooled, homogenized and then plated on this medium. Indicated are the mean pneumococcal CFUs \pm SE of 5 mice and are representative of three separate experiments. In the brain and blood no pneumococci were detected.

5 **Table 3**

Tissue	Mean CFU (\log_{10})	SE
Brain	0	
Olfactory bulbs	1.38	0.61
ON/E	4.93	0.42
Blood	0	
Trigeminal ganglia	2.08	(pooled)

Gangliosides Inhibit Pneumococcal Colonization

The EF3030 strain was incubated with asialo-GM1 or mixed GLSs micelles in 10 PBS prior to nasal application. The GLS mixture displayed the strongest inhibitory effect and reduced CFU in NW by 10 fold ($P = 0.0365$) when assessed four days after nasal application. The largest decline in CFU as a result of mixed GLS preincubation was seen in the ON/E (617-fold decline; $P = 0.0134$). Just as striking were the differences in the lungs ($P = 0.0320$) (Fig. 3B) and CNS tissue ($P = 0.0078$) (Fig. 3A), 15 where an average of 204 and 166 CFU were present in the controls, while pneumococci were undetectable (detection limit = 3 CFU) when incubated with GLSs. The asialo-GM1 preincubation was less efficient than mixed GLSs but still reduced colonization 25- and 63- fold in CNS (Fig. 3A) and lungs (Fig. 3B), respectively. The lungs were infected by inhaled pneumococci and their attachment to asialo-GM1, 20 relatively abundantly present in lungs, was apparently inhibited by GLSs. This indicates that GLSs play a role in the initial attachment to epithelial cells. GLS

treatments did not change pneumococcal viability. No pneumococci were detected in the blood during these experiments. Thus, GLSs constitute an important target for pneumococcal attachment to neuro-epithelium of the nasal tract and infection of lungs and CNS.

5 **Detection Of *S. pneumoniae* Accumulation In The OBs Following Nasal Challenge**

The numbers of EF3030 in OBs were generally too low to make visualization of bacteria by microscopy feasible. To visualize *S. pneumoniae* in the OBs after nasal application, a more virulent strain, TIGR4, was used. Blood samples were tested from representative mice at 1, 3, 6, 12 or 24 hrs after challenge and on every subsequent 10 day. No bacteremia was observed. The mice were sacrificed one week after challenge and tissues were analyzed for CFU (Fig. 4A and 4B). A dose of only 5×10^5 TIGR4 CFU resulted in ~300 CFU in the OBs (Fig. 3). The pneumococci were visualized by staining with PspA-specific Abs in the OBs (Fig. 4D-F). Pneumococci were detected in the OBs, i.e., the glomerular layer (Fig. 4F) and the external plexiform layer (Fig. 15 4E) of challenged mice. Pneumococci were absent in the OBs of control mice (Fig. 4D).

The TIGR4 strain was also detected by PCR amplification of the pneumolysin gene from the NWs, ON/E and OBs 6 days after nasal administration (Fig. 4C). No PCR-detectable pneumococci were present in the bloodstream taken at this interval, or 20 in any samples from non-infected mice.

Example 2

The Role of Pneumococcal Neuraminidases on Neuronal Targeting After Nasal Challenge

To address the importance of neuraminidases, a *nanA* mutant was generated on 25 the TIGR4 background. Pneumococcal mutants are made by insertion-duplication mutagenesis using techniques similar to those used to prepare mutants in *pspA*, *cpbA*

and a *pspA/cbpA* double mutant (Balachandran et al., *Infect. Immun.* 70: 2526-2534, which is incorporated herein by reference in its entirety for its teaching of insertion-duplication mutagenesis techniques). A *nanB* mutant was produced on the TIGR4 background. The NanA-deficient mutants are tested in comparison to their parent 5 strain. A *nanA/nanB* double mutant is produced on the TIGR4 background. The double mutant is compared with each single neuraminidase mutant and with the wildtype TIGR4 strain. Tissues, such as blood, nasal wash, ON/E, OBs, brain are collected at various times (day 1, 4, 11, and 18) after nasal challenge and analyzed for the presence of pneumococcal CFU. The NanB-deficient strain is made with a 10 different antibiotic insert than NanA to facilitate the subsequent production of the *nanA/nanB* double mutant. Using pneumococcal transformation these mutants are moved into various pneumococcal backgrounds such EF3030 to confirm their roles in nasal colonization (Yother et al., (1986) *J. Bacteriology* 168: 1463-1465; Brooks-Walter et al., (1999) *Infect. Immun.* 67: 6533-6542, which are incorporated herein by 15 reference for teaching moving into various pneumococcal backgrounds.). These neuraminidase mutants provide important information on the differential contribution of NanA and NanB on nasal colonization and subsequent invasion of the CNS.

In vitro studies

The ability of the TIGR4, and its *nanA* and *nanB* mutants to bind to specific 20 gangliosides is measured. The gangliosides used include mixed gangliosides, asialo-GM1, GM1, GD1a, GD1b, GT1 (Calbiochem) and the GM3 ganglioside (Sigma). The GM3 ganglioside lacks the terminal or internal GalNAc β 1-4Gal sequence involved in pneumococcal binding and is used as a negative control. These mixed, mono-, di- or tri-sialic acid containing gangliosides bind readily to ELISA plates. Initial data 25 following short-term incubation with the TIGR4 strain indicates that pneumococci bind to asialo-GM1-coated plates but not to BSA-, GM-3, or GM1-coated plates. Using ganglioside-coated plates, the ability to attach to these plates by wildtype TIGR4 strain, the stable opaque and transparent phase variants of the TIGR4 strain,

the *nanA*, *nanB*, and *nanA/nanB* mutant strains is compared. These analyses include short-term incubation (1 hr) and extended incubations (24 hrs) on ganglioside-coated plates. Attached pneumococci are removed from the ganglioside plates by short incubation (10-15 min.) in Todd Hewitt medium containing 0.5% yeast extract

5 followed by repeated pipetting and plating the released bacteria on blood agar plates. Alternatively 41° C Todd Hewitt broth agar containing 0.5% yeast extract is poured on top of the attached pneumococci and the colonies are counted through the bottom of the plate. Controls include plates with no pneumococci and plates with no gangliosides but with pneumococci.

10 Subsequent to testing ganglioside binding, different cell lines are tested for their ability to attach pneumococci to their cell surface and internalize them. These studies focus on the rat neuronal pheochromocytoma cell line PC12 (ATCC) and the macrophage cell line P388D1. These two cell lines were chosen because of their specific attributes. The P388D1 cell line expresses high affinity PAF-R (Valone

15 (1988) *J. Immunol.* 140: 2389-2394), which has been reported to be present on microglia. The PC12 cell line does not express detectable PAF-R. Brewer et al., (2002) *J. NeuroChem* 82: 1502-1511. Between 10^2 - 10^5 pneumococcal CFU are added to these cell lines grown in 6 well or 24 well tissue culture plates and are incubated at 37° C for between 15 min. to 6 hrs after which the cells are extensively washed and

20 adherent pneumococci analyzed. To determine internalization into the cells a 2 hr wash with penicillin and gentamicin is performed prior to plating the cells on blood agar or over-laying them with 41° C Todd Hewitt broth agar containing 0.5% yeast extract. The two cell lines used reflect *in vivo* expression of the PAF-R normally observed in the CNS. While activated microglia abundantly express this receptor as

25 does the P388D1 cell line, the PAF-R receptor is either absent on neuronal cells, such as the PC12 cell line, or is only expressed at low levels by discrete neuronal subpopulations. Mori et al., (1996) *J. Neurosci* 16: 3590-3600; Bennett et al., (1998) *Cell Dath Differ.* 5: 867-875. Adherence of pneumococci to both cell lines would indicate that the PAF-R is not essential for adherence and alternative receptor exist.

The TIGR4 opaque and transparent variants and the *nanA*-, *nanB*-mutants and *nanA/nanB* double mutant are tested for adherence to these cell lines relative to that observed with the wildtype TIGR4 strain. To further analyze the role of PAF-R versus gangliosides in pneumococcal adherence, the COS-7 cell line (Gerard and

5 Gerard (1994) J. Immunol. 152: 793-800; Honda et al., (1992) J. Lipid Med. 5: 105-107), which lack PAF-R, are transfected with the human PAFR open reading frame of 1029 bp using the pcDNA3.1/GS plasmid as previously reported (Brewer et al., (2002) J. Neuro Chem 82: 1502-1511, which is incorporated herein by reference in its entirety for the methods taught therein) and tranfected using Transfast reagent

10 (Promega). The plasmid alone is used as a control and the parameters influencing pneumococcal adherence are analyzed in the presence or absence of PAF-R. This experiment provides unequivocal data regarding the importance of PAF-R in adherence. Any adherence in PAF-R deficient cell lines is mediated by gangliosides and is subsequently blocked by preincubation with gangliosides. To further address

15 the ability of pneumococci to attach to and penetrate epithelial cells the Detroit 562 human pharyngeal epithelial cell line (ATCC) and A549 human pulmonary epithelial cell line (ATCC) is employed using a transwell system. The Millicell®-PCF Culture plate inserts are used to grow the epithelial cell lines to confluence. Confluence is determined by measuring the transepithelial resistance using a Millipore Millicell

20 electrical resistance system. A resistance of at least 500 Ω per cm² indicates that a fully confluent epithelial monolayer is achieved. These cells are exposed to pneumococci to test their ability to attach to, enter into and penetrate this epithelial layer. To distinguish attachment versus internalization the epithelial cells are washed and incubated for 2 hrs with medium containing penicillin and gentamycin. The

25 initial focus is on the TIGR4 strain, its *nanA* and *nanB* mutants, and the double mutant. Stable transparent and opaque variants of the TIGR4 strain have been generated by sequential passages until stable variants were obtained that did not reverse following *in vivo* challenge. These TIGR4 variants are compared for their ability to adhere to, enter and tranverse epithelial cells. Wells are loaded with 10³-10⁶

CFU/well in EMEM media. At 0.5, 1, 2, 4, 8, and 24 hrs cultures are harvested both above and below the epithelial layer and analyzed for CFU. The cell layers are washed 5-6 times prior to overlaying the cells with Todd-Hewitt broth supplemented with 0.5 % yeast extract and 0.5% agar cooled to 41° C to determine the

5 pneumococcal CFUs associated with the monolayer. The plates are incubated overnight at 37° C and 5% CO₂ after which the CFU are counted. The cell lines are analyzed for expression of the PAF-R. Total RNA derived from these cell lines are analyzed by RT-PCR using the two primers, PAF-1 (5'-CCGATACACTCTTCCCGA-3' (SEQ ID NO:3); nucleotides 151 to 170) and

10 PAF-2 (5'-ACAGTTGGTGCTAAGGAGGC-3' (SEQ ID NO:4); nucleotides 970 to 951) resulting in a 838 bp PCR product (Stengel et al., (1997) *Arterioscler. Thromb. Vasc. Biol.* 17: 954-962, which is incorporated herein in its entirety for the methods taught therein). If the PAF receptor is present PAF receptor inhibitors such as octylonium bromide (Biomol Research Laboratories, Inc. Plymouth meeting, PA) or

15 PAF (Biomol) are added to the cultures to determine the contribution of the PAF-R on epithelial adhesion and penetration. The octylonium bromide binds with high affinity to the PAF-R. Alternatively the above mentioned COS7 cells are used for this purpose and compare pneumococcal adherence in the presence and absence of PAF-R.

The degree of invasiveness of the different pneumococcal strains is correlated
20 with production of inflammatory cytokines in both the apical and basolateral compartment of the Transwell system. The culture supernatants are collected at the various timepoints in both the upper and lower compartment and analyzed by ELISA (BD PharMingen) to determine the concentration of the inflammatory cytokines IL-1 β , IL-6, IL-8, IL-10 and TNF- α . The epithelial monolayers are fixed in acetic alcohol
25 and analyzed for the intracellular presence of pneumococci using PspA-specific immunofluorescent staining as previously used for visualization of pneumococci in OBs. Fluorescent images are visualized with a Leica / Leitz DMRB microscope equipped with appropriate filter cubes (Chromtechnology, Battleboro, VT) as previously described (Martin et al., (1998) *J. Immunol.* 160: 3748-3758, which is

incorporated herein by reference for the methods taught therein). Images are collected with a C5810 digital color camera (Mamamatsu Photonic System) and processed with Adobe photoshop and IP LAB Spectrum software.

Example 3

5 **The Role of Gangliosides in *S. pneumoniae* Pathogenesis**

Purified neuraminidase, NanA (Calbiochem), is administered at 1, 10 and 50 µg in 10 µl PBS nasally 15, 30 and 60 minutes prior to isolating the ON/E. The tissues are fixed in 4 % paraformaldehyde, and paraffin sections made. GM1 is stained for using biotinylated-CT-B followed by Streptavidin-FITC and the intensity 10 of staining is analyzed. The section is also stained by asialo-GM1-specific Abs conjugated to rodamine to confirm a decrease of GM1 staining coincident with increase of asialo-GM1 staining in these tissues. Parallel groups of mice undergoing the same treatment are analyzed for colonization by *S. pneumoniae* strain TIGR4 and EF3030 at days 1 and 4, to assure that neuraminidase treatment resulted in elevated 15 levels of nasal colonization. Mice are given a high dose of strain EF3030 (1×10^8 CFU) nasally and the ON/E is isolated at the following intervals: 1, 3, 6, and 12 hrs, 1 and 4 days after nasal challenge. The ON/E is stained as outlined above and analyzed for GM1 and asialo-GM1 expression. If decreased GM1 and elevated asialo-GM1 expression are observed in the nasal tissues, then the NanA- and NanB-deficient 20 strains are also tested since they would be expected not to alter GM1 expression in the nasal tract. The removal of sialic acid residues exposes the subterminal disaccharide, β-D-galactopyranosyl-(1-3)N-acetyl-D-galactosamine, which represents an immunodominant group of the Thompson-Friedenreich antigen, for which PNA has high affinity. Thus, changes in the PNA-binding sites in the ON/E is another measure 25 of neuraminidase activity. Frozen sections made from these tissues are readily stained with PNA-FITC or PNA-HRP (Medac, Hamburg, Germany) to determine if an increase in PNA-binding sites occurs based on microscopy (Black et al., (2000)

Pediatr. Infect. Dis J. 19: 187-195; Klein et al. (1978) Klin. Wochenschr. 56: 761-765, which are incorporated herein by reference in their entirety for the methods taught therein).

The GM1 site is specifically blocked prior to nasal administration of strain TIGR4 or EF3030. This is approached in three ways by using: 1) CT-B versus a non-ganglioside control protein e.g. ovalbumin, 2) Abs to GM1 (Calbiochem) versus normal rabbit immunoglobulins, or 3) GM1-specific peptides synthesized in the UAB Protein Analysis and Peptide Synthesis Core Facility. The inhibition with the GM1-specific peptide is the best approach since CT-B and possibly Abs to GM1 is expected to cause concomitant inflammation. In these experiments the ON/E and OBs are analyzed 1 and 4 days after application for pneumococcal CFU. An alternative approach of blocking GM1 is the use of a GM1-binding peptide that was discovered by use of a phage-display pentadecapeptide library selecting for GM1-binding peptides. This GM1-binding peptide VWRLLLAPPFSNRLLP (SEQ ID NO:5) has high affinity ($10^{10} M^{-1}$) for GM1 and an IC_{50} of 1.0 μM . Matsubara et al., (1999) FEBS Letters 456: 253-256. A peptide of the same length and composed of the same amino acids in a randomly selected sequence is used as control. The GM1-binding ability of both peptides is confirmed by ELISA prior to use *in vivo*. Initially, 100 μg of these two peptides is administered nasally in 10 μl Ringer's solution or PBS, 10 minutes prior to applying 3×10^6 CFU of strain EF3030. The ON/E is analyzed for CFU on days 1 and 4 after application for numbers of CFU relative to untreated CBA/N mice.

Blocking experiments are performed with PAF (Biomol Research Laboratories, Inc. Plymouth meeting, PA) and the PAF-R antagonist octylonium bromide (Biomol). This compound binds with high affinity to the PAF-R. Each ganglioside is tested individually. Besides mixed gangliosides, asialo-GM1, GM1, GD1a, GD1b, GT1 (Calbiochem) and the GM3 (Sigma) are tested for their ability to inhibit nasal colonization as assessed on day 1 and 4 after challenge. Various gangliosides are able to block this process. The GM3 ganglioside functions as a

negative control since it lacks the published C-polysaccharide binding motif. Based on the data presented on colonization with EF3030 following ganglioside preincubation, mixed gangliosides are more effective than asialo-GM1 at blocking colonization. This indicates that other gangliosides besides asialo-GM1 are involved

5 in the process of pneumococcal colonization of the nasal tract, lungs and brain. These ganglioside inhibition studies focus on the TIGR4 strain and its neuraminidase mutants. Short term *in vitro* incubation with the TIGR4 strain on ganglioside-coated ELISA plates demonstrated attachment of the TIGR4 strain to the asialo-GM1 (Fig.4). Enterotoxins provide another means of differentially blocking pneumococci-

10 ganglioside interactions in the nasal tract. Both CT and LTh-1 are both serogroup I heat-labile enterotoxins (Pickett et al., (1986) *J. Bacteriol* 165: 348-352) and display similar, although slightly different, ganglioside binding specificities. Fukuta et al., (1988) *Infect Immun.* 56: 1748-1753. CT (List Biological Laboratories, Inc., Campbell, CA) binds to GM1 and to a lesser extent to GD1b. LTh-1 displays

15 preferential binding to GM1 and GD1b and binds weakly to GM2 and asialo-GM1. Fukuta et al., (1988) *Infect Immun.* 56: 1748-1753. If GM1 is the main ganglioside interacting with *S. pneumoniae*, the use of LTh-1 would not only block the GM1 ganglioside but might also block asialo-GM1, which could represent a natural low frequency binding site not requiring neuraminidase activity. The heat-labile

20 enterotoxins from serogroup II display different ganglioside binding specificities, in particular the heat-labile enterotoxin LT-IIb. This toxin binds to GD1a and to a lesser extent to GT1b and showed no affinity for GM1. Fukuta et al., (1988) *Infect Immun.* 56: 1748-1753. The LT-IIa binds with high affinity to GD1b and with a lower affinity to GM1, GT1b, GQ1b, GD2, GD1a, and GM2. Fukuta et al., (1988) *Infect Immun.* 56: 1748-1753. The LT-II toxins have been kindly provided by Dr. T.D. Connell. To optimize the nasal dose and the optimal time period to observe inhibition of pneumococcal attachment to ON/E, a dose response study (1.0 or 10 µg) is initially performed on a selected enterotoxin, which is given during nasal application of *S. pneumoniae*. If inhibition of nasal colonization is observed on day 4 the observations

25

are extended to day 11 during which enterotoxin is given every other day. The CFU in ON/E and OBs of CBA/N mice are measured.

Example 4

The Role of C-Polysaccharide-Specific Antibodies in Pneumococcal Pathogenesis

5 Pneumococcal C-polysaccharide, also known as teichoic acid, is structurally identical to the pneumococcal F-antigen, also known as lipoteichoic acid. Fischer et al. (1993) Eur. J. Biochem 215: 851-857. This is a unique feature of *S. pneumoniae* among gram-positive bacteria. The immunodominant determinants on these molecules are the phosphorylcholine (PC) residues and Abs to PC are protective against i.p. or
10 nasal pneumococcal challenge. Briles et al., (1984) Eur. J. Immunol. 14: 1027-1030; Briles et al., (1981) Nature 294: 88-90; Yother et al., (1982) Infect. Immun. 36: 184-188; Briles et al., (1984) J. Mol. Cell. Immunol. 1:305-309. Thus, the role of PC-specific Abs, either obtained by passive transfer or active nasal immunization, is explored. For passive transfer of protective PC-specific Abs, i.e., T15 idiotypic
15 monoclonal Abs (mAbs) of both the IgG3 (59.6C5) and IgM (22.1A4) isotypes are used. Briles et al., (1981) Nature 294: 88-90. The T15 idiotype has been shown to be more protective than the M603 or M511 idiotypes against pneumococcal infection in mice (Briles et al., (1984) Eur. J. Immunol. 14: 1027-1030), presumably by more efficiently binding the C-polysaccharide. Passive Ab transfer involves the direct
20 application of T15 Abs (100 µg) with nasally applied pneumococci and is compared to i.v. or i.p. administered Abs for reducing nasal colonization. Colonization is monitored over time (day 4, 11, 18) and if no significant difference is observed between the different groups in these experiments mAbs (20 µg) are applied nasally every other day. CBA/N mice, do not produce T15 idiotypic anti-PC Abs. Passive
25 transfer of anti-PC-specific Abs is not expected to induce mucosal IgA or other isotypes of PC-specific Abs in the nasal tract. In order to induce nasal Abs, two different approaches are taken. One is the direct nasal application of the protease

treated R36A strain, which is known to induce Ab responses to C-polysaccharide. Although protective immunity of anti-PC Abs has been studied, no data is available on their role at mucosal surfaces such as the nasal tract. The CBA/N mice X-chromosome-linked immunodeficiency results in an inability to generate anti-PC Abs

5 of the T15-idiotype. To determine the importance of this inability CBA/N mice are compared to their wildtype counterpart the CBA/J mice (Jackson Laboratories). Immunization with strain R36A for induction of anti-PC Abs involves proteolytic removal of surface protein. Krause (1970) *Adv. Immunol.* 12: 1-56. The alternative approach for nasal immunization is coupling of PC to the protein keyhole limpet

10 hemocyanin (KLH) as previously described (Krause (1970) *Adv. Immunol.* 12: 1-56; Chesebro and Metzger (1972) *Biochemistry* 11: 766-771, which are incorporated herein by reference for the methods taught therein). Nasal immunization with PC-KLH is performed with the mucosal adjuvant CT to optimize mucosal immune responses. The mice are challenged 2-3 weeks after the last immunization to prevent

15 effects of CT on colonization. Three nasal immunizations are performed at one week intervals. The serum Ab titers are monitored using a C-polysaccharide and PC-specific ELISA as routinely performed by Dr. Moon H. Nahm at UAB. For the PC-specific ELISA, PC is coupled to BSA as described previously (Chesebro and Metzger (1972) *Biochemistry* 11: 766-771, which is incorporated herein by reference for the

20 methods taught therein). In addition to serum, the Ab titers in nasal washes, saliva, and bronchial lavages are measured. These analyses include IgA, IgM, IgG, and IgG-subclass distribution in both mucosal secretions and serum. The protocol that induces the most optimal mucosal Ab titers is used to perform mucosal challenge studies with the TIGR4 strain, which is administered nasally at $\sim 5 \times 10^6$ CFU to mice after which

25 colonization is monitored on day 4 and 11. In the immunization studies normal, fully immunocompetent mice (CBA/J strain) as well as CBA/N mice are used as in previous studies. Wallick et al., (1983) *J. Immunol.* 130: 2871-2875.

Example 5

The Role of Neuraminidase-Specific Antibodies in *S. pneumoniae* Pathogenesis

To nasally immunize the mice prior to nasal challenge commercially available *S. pneumoniae*-derived neuraminidase is used (Calbiochem). However, the NanA gene is cloned and expressed in *E. coli* using a histidine-tag containing expression vector (Invitrogen) in order to obtain sufficient amounts of protein for the proposed studies. Nasal immunization of 3.4% formaldehyde-treated neuraminidase is compared versus-untreated neuraminidase in the presence or absence of CT in order to optimize the mucosal immune responses. These immunizations are performed in both 10 CBA/N and CBA/J mice. Three nasal immunizations are given one week apart during which serum and saliva Abs titers are monitored by ELISA. The immune mice are challenged with the TIGR4 strain and the colonization of ON/E, OB, brain, blood, spleen, and lungs is compared on days 4 and 11. To block host interaction, both neuraminidase and C-polysaccharide-specific Abs are induced simultaneously. A 15 combined regimen of nasal immunization with neuraminidase and passive immune protection by transfer of T15 idiotypic mAbs is used.

Example 6

The Efficacy of Neuraminidase-PC Conjugate to Protect Against Nasal Challenge with *S. pneumoniae*

20 Mice are immunized with neuraminidase and PC-KLH in combination with CT as nasal adjuvant to assess enhancement of protection and decrease nasal colonization by the EF3030 and TIGR4 strains on day 11 compared to each antigen used alone. In addition, Ab titers in nasal washes, saliva, and serum are analyzed as indicated above to correlate immune parameters with degree of protection to 25 pneumococci in the nasal tract. To generate a more optimal immune response phosphocholine is directly coupled to neuraminidase. This construct is tested for

immunogenicity when delivered with or without CT as adjuvant after nasal and systemic immunization in both CBA/N and CBA/J mice. The Ab titers in nasal washes, saliva, and plasma are measured by ELISA. Challenge studies are performed with 10^7 CFU of strains EF3030 or 10^6 TIGR4. The mice are sacrificed on day 11
5 after challenge and analyzed for CFUs observed in blood, nasal washes, ON/E, OB, and brain. Immunization with neuraminidase coupled to PC enhances protection by increasing mucosal and systemic Ab levels to these two virulence components. The antigen-specific IgG subclass distribution are altered by using other mucosal adjuvants. CT generates a Th2-, LT a mixed Th2/Th1-, and CpG motifs such as the
10 DNA oligonucleotide (ODN) 1826 a Th1-type response with associated changes in IgG subclass distribution. Different adjuvants further enhance the ability of neuraminidase-C-polysaccharide-specific immunity to protect against nasal colonization by *S. pneumoniae* and lead to the formulation of new pneumococcal vaccine approaches.

15 **Example 7**

Inhibition of nasal colonization of *S. pneumoniae* by anti-phosphocholine-specific monoclonal antibodies after nasal challenge.

A total of 1×10^6 CFU of the TIGR4 strain were incubated with 5 μ g of anti-phosphocholine monoclonal antibodies of either the IgG3 subclass or IgM isotype. A
20 total of 5 μ l was administered per nare. Indicated are the CFUs in 500 ml nasal wash respectively 9 and 12 hours after application. A significant over 80 % decrease was observed for both monoclonal antibodies. Indicated are the mean + SD of five mice per group. The data are shown in Figure 5.

Example 8

Pneumococcal neuraminidase mutants are unable to colonize the nasal tract.

The neuraminidase mutant of *nanA* or the double mutant *nanA/nanB* were administered in 10 μ l nasally in unanesthetized mice and were compared with the 5 parent wildtype strain TIGR4. The data are shown in Figure 6. After six days the nasal wash, olfactory nerves and epithelium (ON/E), olfactory bulbs and brain were analyzed for CFUs. As illustrated above, no nasal colonization or invasion into the olfactory bulbs was observed. Indicated are the mean of three mice per group.

Example 9

10 **Neuronal damage and inflammation after nasal *S. pneumoniae* application**

The ON/E, OB, and brain are isolated from treated mice at days 1, 3, 7, and 14 after nasal application of *S. pneumoniae* strain EF3030 and analyzed histologically for inflammatory responses. The D39 or TIGR4 strains are compared to their *nanA* mutant strains for their ability to generate inflammatory responses. At sacrifice, the 15 mice are perfused with PBS at 25° C, followed by perfusion with 10 ml of Zamboni's fixative (4 % paraformaldehyde, 15 % picric acid in 0.1 M phosphate buffer. The OB and ON/E are removed and then placed in fresh 4 % paraformaldehyde (PFA) at 4° C overnight. The tissue is then transferred to a 30 % sucrose solution at 4° C for 48 hr to cryoprotect it prior to sectioning. The tissues are then frozen in OCT and sections 20 (6 μ m) are placed on previously coated microscope slides (10 % BSA in saline). Initially, hematoxylin and eosin (H&E) staining are performed to detect any inflammatory cell infiltrates in the OB, trigeminal ganglia and ON/E during this time period. In order to assess neuronal damage, we will stain for nerve growth factor β 1 (NGF- β 1). NGF- β 1 is produced after neuronal damage and functions to prevent 25 apoptosis and to stimulate new growth of nerve cells. Trigeminal ganglia and OB sections will be stained with a biotinylated rabbit anti-human NGF- β 1 Ab at a

concentration 0.2 μ g/ml. The Ab-stained sections are incubated at 4° C overnight. The slides are rinsed with PBS and then reacted with avidin-biotin-complex (ABC) Vectastain (Vector Laboratories, Burlingame, CA) for 30 min at 25° C. The tissue is rinsed 3 times with PBS and then reacted with diaminobenzidine (DAB) for 5 - 10
5 min as previously reported. The slides are rinsed 3 more times and sections counterstained with C.S. hematoxylin for 30 sec. After washing in H₂O, the slides are dehydrated in 100 % alcohol and xylene. An increase in NGF- β 1 will provide us with an indication of the degree of damage in neuronal tissues. Another indicator for neuronal involvement is the activation of microglia. Activated microglia display an
10 amoeboid, spherical shape while resting cells (in G₀/G₁) have an arborized, ramified appearance. This change upon activation allows one to distinguish resting and activated microglia. For microglia, F4/80 antibody or anti-MAC-1 (MI/70) will be used to address the activation state after *S. pneumoniae* challenge. In addition to neuronal damage and microglia activation, the induction of apoptosis in OB is
15 assessed. To this end, the induction of active Caspase 3, an Asp-Glu-Val-Asp specific protease, is analyzed because it is important in the initiation of apoptotic pathways. An Ab specific for active Caspase 3 (Cell Signaling Technology, Inc., Beverly, MA) can be used in immunohistochemistry for detection of apoptosis. If Caspase 3 activity is detected in neuronal tissues by immunohistochemistry, activity is quantified using a
20 Caspase-3 Assay kit (Molecular probes, Eugene, OR) based on a fluorescent signal induced after proteolysis of the substrate.

Example 10

Ability of *S. Pneumoniae* to target olfactory bulbs by retrograde axonal transport

25 First, accumulation of pneumococci in the neuronal tissues, OB and brain, of treated mice following nasal and i.v. inoculation is assessed. Following i.v.

inoculation, any pneumococci in the neuronal tissues has entered through the blood. Tissues at 1, 4, 11 and 18 days following nasal challenge are collected. In that case the numbers of bacteria per gram of brain and OB should be similar at all time points post injection. In contrast, for bacteria entering through the nasal tract following intranasal 5 inoculation, an accumulation in the OB (expressed per weight of tissue) precedes and in general remains ahead the accumulation observed in the brain.

Second, *in vivo* imaging of pneumococci after nasal application is performed. Technetium-99 (Tc-99m)-labeled TIGR4, stable opaque and transparent variants, 10 EF3030, and TIGR4 mutants lacking *nanA* and/or *nanB* are used to visualize their presence in mice using gamma camera imaging as previously performed with adenovirus using a strategy originally described by Waibel et al. (1999) *Nature Biotechnol.* 17:897-901. This allows imaging for approximately the first 24 hrs following nasal application due to the short half live (6 hrs) of this isotope and allows analysis of the early events taking place in the nasal tract. For long term imaging of 15 the pneumococci, a luciferase-or GFP-expressing pneumococcal EF3030 (or TIGR4) strain are used to visualize the bioluminescence *in vivo*. A luciferase-expressing pneumococci strain EF3030, commercially available from the Xenogen corporation, is used. Successful *in vivo* imaging with this pneumococcal strain has been previously reported. The mice are imaged using a bioluminescence imaging system (IVIS system, 20 Xenogen, Inc.) to detect luciferase expression. Images are collected on mice oriented in the same position and always at 10 min after i.p. injection of 2.5 mg luciferin. During imaging the mice are maintained under enflurane anesthesia at 37° C. Imaging is performed several times on each mouse, beginning at 2 days to 18 days after nasal challenge with luciferase-expressing pneumococci. Image acquisition times for 25 imaging are in the range of 20 sec to 10 min. Data acquisition software insures that no pixels are saturated during image collection. Light emission from the regions of interest (relative photons/sec) are quantitated using software provided by Xenogen. The intensity of light emission is represented with a pseudocolor scaling of the bioluminescent images. The bioluminescent images are typically over-layed on black

and white photographs of the mice that are collected at the same time. This *in vivo* imaging focuses on analyzing the ability of pneumococci to enter the OBs from the nasal tract. This bioluminescence studies extend to the *nanA* TIGR4 mutant after successful transfer of the luciferase gene.

5 Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the compounds, compositions and methods described herein.

10 Various modifications and variations can be made to the compounds, compositions and methods described herein. Other aspects of the compounds, compositions and methods described herein will be apparent from consideration of the specification and practice of the compounds, compositions and methods disclosed herein. It is intended that the specification and examples be considered as exemplary.

References

15 Quagliarello, V. and Scheld, W.M. 1992. Bacterial menigitis: pathogenesis, pathophysiology, and progress. *N. Eng. J. Med.* 327: 864-872.

Anon. 2000. Surveillance of preliminary reports from 18 countries and the USA. CDSC European Bacterial Meningitis Surveillance Project. PHLS, London.

20 Fedson, D.S., Shapiro, E.D., LaForce, F.M., Mufson, M.A., Musher, D.M., Spika, J.S., Breiman, R.F. and Broome, C.V. 1994. Pneumococcal vaccine after 15 years of use. Another view. *Arch. Intern. Med.* 154:2531-2535.

Butler, J. C. and Schuchat, A. 1999. Epidemiology of pneumococcal infections in the elderly. *Drugs Aging* 15(Suppl. 1):11-19.

Fedson, D. S., Scott, J.A. and Scott. G. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known [In Process Citation]. *Vaccine*. 17 Suppl. 1:S11-18.

Tong, H.H., Blue, L.E., James, M.A., and DeMaria, T.F. 2000. Evaluation of the 5 virulence of a *Streptococcus pneumoniae* neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model. *Infect. Immun.* 68: 921-924.

O'Toole, R.D., Goode, L., and Howe, C. 1971. Neuraminidase activity in bacterial meningitis. *J. Clin Invest.* 50: 979-985.

10 Kelly, R.T., Farmer, S., and Greiff, D. 1967. Neuraminidase activities of clinical isolates of *Diplococcus pneumoniae*. *J. Bacteriol.* 94: 272-273.

Vishniakova, L.A., Reztsova, I.V. 1992. The virulence of *Streptococcus pneumoniae* strains—the causative agents of pneumococcal infection at different sites. *Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii*. 9-10:26-9.

15 Fischer, W., Behr, T., Hartmann, R., Peter-Katalinic, J., and Egge, H. 1993. Teichoic acid and lipoteichoic acid of *Streptococcus pneumoniae* posses identical chain structure. A reinvestigation of teichoic acid (C polysaccharide). *Eur. J. Biochem.* 215: 851-857.

Briles, D.E., Forman, C., Hudak, S., and Claflin, J.L. 1984. The effects of idiotype on 20 the ability of IgG1 anti-phosphorycholine antibodies to protect mice from fatal infection with *Streptococcus pneumoniae*. *Eur. J. Immunol.* 14: 1027-1030.

Briles, D.E., Chaflin, J.L., Schroer, K., and Forman, C. 1981. Mouse IgG3 antibodies are highly protective against infection against *Streptococcus pneumoniae*. *Nature* 294: 88-90.

Yother, J., Forman, C., Gray, B.M., and Briles, D.E. 1982. Protection of mice from infection with *Streptococcus pneumoniae* by anti-phosphocholine antibody. *Infect. Immun.* 36: 184-188.

Briles, D.E., Forman, C., Hudak, S., and Claflin, J.L. 1984. The effects of subclass on the ability of anti-phosphocholine antibodies to protect mice from fatal infection with *Streptococcus pneumoniae*. *J. Mol. Cell. Immunol.* 1: 305-309.

Lock, R. A., Paton, J.C., and Hansman, D. 1988. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against *Streptococcus pneumoniae*. *Microb. Pathog.* 5(6): 461-7.

10 Berry, A.M., Lock, R.A., and Paton, J.C. 1996. Cloning and characterization of nanB, a second from *S. pneumoniae* neuraminidase gene, and purification of the NanB enzyme from recombinant *Escherichia coli*. *J. Bacteriol.* 178: 4854-4860.

Scanlon, K.L., Diven, W.F., Glew, R.H. 1989. Purification and properties of *Streptococcus pneumoniae* neuraminidase. *Enzyme* 41: 143-150.

15 Remington's Pharmaceutical Sciences, latest edition, by E.W. Martin Mack Pub. Co., Easton, PA.

Smith and Waterman (1981) *Adv. Appl. Math.* 2: 482.

Needleman and Wunsch, (1970) *J. Mol. Biol.* 48: 443.

Pearson and Lipman, (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85: 2444.

20 Zuker, M.(1989) *Science* 244:48-52.

Jaeger et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:7706-7710.

Jaeger et al. (1989) *Methods Enzymol.* 183:281-306.

Pastan et al., Proc. Natl. Acad. Sci. U.S.A. 85:4486, 1988.

Miller et al., Mol. Cell. Biol. 6:2895, 1986.

Mitani et al., Hum. Gene Ther. 5:941-948, 1994.

Goodman et al., Blood 84:1492-1500, 1994

5 Naidini et al., Science 272:263-267, 1996

Agrawal et al., Exper. Hematol. 24:738-747, 1996

Schwartzberger et al., Blood 87:472-478, 1996

Crystal, Hum. Gene Ther. 8:985-1001, 1997

Alvarez and Curiel, Hum. Gene Ther. 8:597-613, 1997

10 Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.

Harlow and Lane. Antibodies, A Laboratory Manual. Cold Spring Harbor Publications, New York, (1988).

Kohler and Milstein, Nature, 256:495 (1975).

15 Zoller, M.J. Curr. Opin. Biotechnol. 3:348-354, 1992.

Cole et al. (Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77, 1985)

Boerner et al. (J. Immunol., 147(1):86 95, 1991).

Hoogenboom et al., J. Mol. Biol., 227:381, 1991;

Marks et al., J. Mol. Biol., 222:581, 1991).

20 Jakobovits et al., Proc. Natl. Acad. Sci. USA, 90:2551 255 (1993);

Jakobovits et al., *Nature*, 362:255 258 (1993);
Bruggermann et al., *Year in Immunol.*, 7:33 (1993)).
Jones et al., *Nature*, 321:522 525 (1986),
Reichmann et al., *Nature*, 332:323 327 (1988)
5 Presta, *Curr. Opin. Struct. Biol.*, 2:593 596 (1992)).
Jones et al., *Nature*, 321:522 525 (1986),
Riechmann et al., *Nature*, 332:323 327 (1988),
Verhoeven et al., *Science*, 239:1534 1536 (1988)),
Avery, O.T., MacLeod, C.M., and McCarty, M. 1944. *J. Exp. Med.* 79:137-158.
10 Briles, D.E., Crain, M.J., Gray, B.M., Forman, C., and Yother, J. 1992. *Infect. Immun.* 60: 111-116.
Amsbaugh, D.F., Hansen, C.T., Prescott, B., Stashak, P.W., Barthold, D.R., and
Baker, P.J. (1972) *J. Exp. Med.* 136: 931-949.
Berning, A.K., Eicher, E.M., Paul, W.E., and Scher, I. (1980) *J. Immunol.* 124: 1875-
15 1877.
van Ginkel, F.W., Jackson, R.J., Yuki, Y., and McGhee, J.R.. (2000) *J. Immunol.*
(Cutting Edge) 165: 4778-4782.
Wu, H-Y., Nguyen, H.H., and Russell, M.W. (1997) *Scand. J. Immunol.* 46: 506-513.
Ausubel, F.M., Brent, R., Kingston, R.E., Moore, D.D., Seidman, J.G., Smith, J.A.
20 and Struhl, K. (Eds.). (1987) *Current Protocols in Molecular Biology*. Greene
Publishing Associated, 2nd Wiley-Interscience, Section 2.4.4.

Magee, A. and Yother, J. (2001) *Infect. Immun.* 69: 3755-3761.

Balachandran, P., Brooks-Walters, A., Virolainen-Julkunen, A., Hollingshead, and Briles, D.E. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of 5 *Streptococcus pneumoniae*. *Infect. Immun.* 70: 2526-2534.

Yother, J., McDaniel, L.S., and Briles, D.E. 1986. Transformation of encapsulated *Streptococcus pneumoniae*. *J. Bacteriology* 168:1463-1465.

Brooks-Walter, A., Briles, D.E., and Hollingshead, S.K. 1999. The PspC gene of *Streptococcus pneumoniae* encodes a polymorphic protein, PspC, which elicits cross-reactive antibodies to PspA and provides immunity to pneumococcal bacteraemia. 10 *Infect. Immun.* 67:6533-6542.

Valone, F.H. 1988. Identification of platelet-activating factor receptor in P388D1 murine macrophages. *J. Immunol.* 140:2389-2394.

Brewer, C., Bonin, F., Bullock, P., Nault, M.C., Morin, J., Imbeault, S., Shen, T.Y., 15 Franks, D.J. and Bennett, S.A. 2002. Platelet activating factor-induced apoptosis is inhibited by ectopic expression of the platelet activating factor G-protein coupled receptor. *J. NeuroChem.* 82: 1502-1511.

Mori, M., Aihara, M., Kume, K., Hamanoue, M., Kohsaka, S. and Shimizu, T. 1996. Predominant expression of platelet-activating factor receptor in rat brain microglia. J. 20 *Neurosci.* 16:3590-3600.

Bennett, S.A.L., Chen, J., Pappas, B.A., Roberts, D.C.S. and Tenniswood, M. 1998. Alterations in platelet activating factor receptor expression associated with neuronal apoptosis in an in vivo model of excitotoxicity. *Cell Death Differ.* 5: 867-875.

Gerard, N.P., Gerard, C. 1994. Receptor-dependent internalization of platelet-activating factor. *J. Immunol.* 152: 793-800. 25

Honda, Z., Nakamura, M., Seyama, Y., Shimizu, T. 1992. Properties of the guinea-pig lung platelet-activating factor receptor encoded by the cloned cDNA. *J. Lipid Med.* 5: 105-107.

Stengel, D., Antonucci, M., Arborati, M., Hourton, D., Griglio, S., Chapman, M.J.,
5 and Ninio, E. Expression of the PAF receptor in human monocyte-derived macrophages is downregulated by oxidized LDL: relevance to the inflammatory phase of atherosclerosis. (1997) *Arterioscler. Thromb. Vasc. Biol.* 17: 954-962.

Martin, F., Won, W-J. and Kearney, J.F. 1998. Generation of the germline peripheral B cell repertoire: VH81X- \square B cells are unable to complete all developmental
10 programs. *J. Immunol.* 160: 3748-3758.

Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L.,
Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger,
R., Watson, W., Austrian, R., and Edwards, K. 2000. Efficacy, safety and
immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *Pediatr.
15 Infect. Dis. J.* 19: 187-195.

Klein, P.J., Newman, R.A., Muller, P., Uhlenbruck, G., Schaefer, H.E., Lennartz, K.J.,
and Fischer, R. 1978. Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue sections. *Klin. Wochenschr.* 56:
761-765.

20 Matsubara, T., Ishikawa, D., Taki, T., Okahata, Y., and Sato, T. 1999. Selection of ganglioside GM1-binding peptides by using phage library. *FEBS Letters* 456:253-256.

Pickett, C.L., Twiddy, E.M., Belisle, B.W., and Holmes, R.K. 1986. Cloning of genes that encode a new heat-labile enterotoxin of *Escherichia coli*. *J. Bacteriol.* 165:
25 348-352.

Fukuta, S., Magnani, J.L., Twiddy, E.M., Holmes, R.K., and Ginsburg, V. 1988. Comparison of the carbohydrate-binding specificities of cholera toxin and *Escherichia coli* heat-labile enterotoxins LT₁, LT_{2a}, and LT_{2b}. *Infect. Immun.* 56: 1748-1753.

5 Fischer, W., Behr, T., Hartmann, R., Peter-Katalinic, J., and Egge, H. 1993. Teichoic acid and lipoteichoic acid of *Streptococcus pneumoniae* posses identical chain structure. A reinvestigation of teichoic acid (C polysaccharide). *Eur. J. Biochem.* 215: 851-857.

Briles, D.E., Forman, C., Hudak, S., and Claflin, J.L. 1984. The effects of idiotype on 10 the ability of IgG1 anti-phosphorycholine antibodies to protect mice from fatal infection with *Streptococcus pneumoniae*. *Eur. J. Immunol.* 14: 1027-1030.

Briles, D.E., Chaflin, J.L., Schroer, K., and Forman, C. 1981. Mouse IgG3 antibodies are highly protective against infection against *Streptococcus pneumoniae*. *Nature* 294: 88-90.

15 Yother, J., Forman, C., Gray, B.M., and Briles, D.E. 1982. Protection of mice from infection with *Streptococcus pneumoniae* by anti-phosphocholine antibody. *Infect. Immun.* 36: 184-188.

Briles, D.E., Forman, C., Hudak, S., and Claflin, J.L. 1984. The effects of subclass on 20 the ability of anti-phosphocholine antibodies to protect mice from fatal infection with *Streptococcus pneumoniae*. *J. Mol. Cell. Immunol.* 1: 305-309.

Krause, R.M. 1970. The search for antibodies with molecular uniformity. *Adv. Immunol.* 12:1-56.

Chesebro, B. and Metzger, H. 1972. Affinity labeling of a phosphorylcholine binding mouse myeloma protein. *Biochemistry* 11:766-771.

Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., Abram, U., Mach, J.P., Pluckthun, A., and Schubiger, P.A. 1999. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. *Nature Biotechnol.* 17:897-901.

5 Crennell SJ, Garman EF, Laver WG, Vimr ER, Taylor GL (1993) Crystal structure of a bacterial sialidase (from *Salmonella typhimurium* LT2) shows the same fold as an influenza virus neuraminidase. *Proc Natl Acad Sci U S A.* 90(21):9852-56.

Lysenko, E.S., J. Gould, R. Bals, J.M. Wilson, and J.N. Weiser. (2000) Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-
10 37/hCAP18 expressed in the upper respiratory tract. *Infect Immun* 68: 1664-71.

Sung, C.K., Li, H., Claverys, J.P., and Morrison, D.A. (2001) An *rspL* cassette, janus, for gene replacement through negative selection in *Streptococcus pneumoniae*. *Appl Environ Microbiol* 67: 5190-5196.

What is claimed is:

1. A detoxified pneumococcal neuraminidase or an antigenic portion thereof.
2. A composition comprising the detoxified neuraminidase of claim 1 and a pharmaceutically acceptable carrier.
3. The composition of claim 2, further comprising an adjuvant.
4. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising administering to the subject the neuraminidase of claim 1.
5. A method of reducing pneumococcal nasal carriage in a subject comprising administering to the subject the neuraminidase of claim 1.
6. A method of preventing pneumococcal infection in a subject comprising administering to the subject the neuraminidase of claim 1.
7. The method of claim 6, wherein the pneumococcal infection is meningitis.
8. The method of claim 6, wherein the pneumococcal infection is otitis media.
9. The method of claim 6, wherein the pneumococcal infection is pneumonia.
10. The method of claim 6, wherein the pneumococcal infection is hemolytic uremia.
11. A method of reducing or preventing pneumococcal nasal carriage in a subject comprising administering to the subject a pneumococcal neuraminidase or an antigenic fragment thereof under conditions that reduce or prevent the nasal carriage.

12. A method of reducing or preventing pneumococcal infection in a subject comprising administering to the subject a pneumococcal neuraminidase or an antigenic fragment thereof under conditions that reduce or prevent the infection.
13. The method of claim 12, wherein the pneumococcal infection is meningitis.
14. The method of claim 12, wherein the pneumococcal infection is otitis media.
15. The method of claim 12, wherein the pneumococcal infection is pneumonia.
16. The method of claim 12, wherein the pneumococcal infection is hemolytic uremia.
17. A composition comprising a pneumococcal neuraminidase or an antigenic portion thereof and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface.
18. The composition of claim 17, wherein the composition is a nasal spray.
19. The composition of claim 17, wherein the composition is a nebulizer solution.
20. The composition of claim 17, wherein the composition is an aerosol inhalant.
21. A container comprising the composition of claim 17.
22. The container of claim 21, wherein the container is a nasal sprayer.
23. The container of claim 21, wherein the container is a nebulizer.
24. The container of claim 21, wherein the container is an inhaler.

25. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 1.
26. A method of reducing pneumococcal nasal carriage in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 1.
27. A method of preventing pneumococcal infection in a subject comprising contacting a mucosal surface of the subject with the composition of claim 1.
28. The method of claim 27, wherein the pneumococcal infection is meningitis.
29. The method of claim 27, wherein the pneumococcal infection is otitis media.
30. The method of claim 27, wherein the pneumococcal infection is pneumonia.
31. The method of claim 27, wherein the pneumococcal infection is hemolytic uremia.
32. A composition comprising a phosphocholine or an antigenic portion thereof of pneumococcal teichoic acid or pneumococcal lipoteichoic acid and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface.
33. The composition of claim 32, wherein the composition is a nasal spray.
34. The composition of claim 32, wherein the composition is a nebulizer solution.
35. The composition of claim 32, wherein the composition is an aerosol inhalant.
36. A container comprising the composition of claim 32.

37. The container of claim 36, wherein the container is a nasal sprayer.
38. The container of claim 36, wherein the container is a nebulizer.
39. The container of claim 36, wherein the container is an inhaler.
40. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 32.
41. A method of reducing pneumococcal nasal carriage in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 32.
42. A method of reducing or preventing pneumococcal infection in a subject comprising contacting a mucosal surface of the subject with the composition of claim 32.
43. The method of claim 42, wherein the pneumococcal infection is meningitis.
44. The method of claim 42, wherein the pneumococcal infection is otitis media.
45. The method of claim 42, wherein the pneumococcal infection is pneumonia.
46. The method of claim 42, wherein the pneumococcal infection is hemolytic uremia.
47. A composition comprising a pneumococcal neuraminidase or an antigenic portion thereof, a phosphocholine or an antigenic portion thereof of pneumococcal teichoic acid or pneumococcal lipoteichoic acid, and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface.

66
ATTORNEY DOCKET NO. 21085.0067U1

48. The composition of claim 47, wherein the composition is a nasal spray.
49. The composition of claim 47, wherein the composition is a nebulizer solution.
50. The composition of claim 47, wherein the composition is an aerosol inhalant.
51. A container comprising the composition of claim 47.
52. The container of claim 51, wherein the container is a nasal sprayer.
53. The container of claim 51, wherein the container is a nebulizer.
54. The container of claim 51, wherein the container is an inhaler.
55. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 47.
56. A method of reducing pneumococcal nasal carriage in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 47.
57. A method of preventing pneumococcal infection in a subject comprising contacting a mucosal surface of the subject with the composition of claim 47.
58. The method of claim 57, wherein the pneumococcal infection is meningitis.
59. The method of claim 57, wherein the pneumococcal infection is otitis media.
60. The method of claim 57, wherein the pneumococcal infection is pneumonia.
61. The method of claim 57, wherein the pneumococcal infection is hemolytic uremia.

62. A composition comprising a non-phosphocholine antigenic portion of pneumococcal teichoic acid or pneumococcal lipoteichoic acid and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface.
63. The composition of claim 62, wherein the composition is a nasal spray.
64. The composition of claim 62, wherein the composition is a nebulizer solution.
65. The composition of claim 62, wherein the composition is an aerosol inhalant.
66. A container comprising the composition of claim 62.
67. The container of claim 66, wherein the container is a nasal sprayer.
68. The container of claim 66, wherein the container is a nebulizer.
69. The container of claim 66, wherein the container is an inhaler.
70. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 62.
71. A method of reducing pneumococcal nasal carriage in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 62.
72. A method of preventing pneumococcal infection in a subject comprising contacting a mucosal surface of the subject with the composition of claim 62.
73. The method of claim 72, wherein the pneumococcal infection is meningitis.

74. The method of claim 72 , wherein the pneumococcal infection is otitis media.
75. The method of claim 72 , wherein the pneumococcal infection is pneumonia.
76. The method of claim 72 , wherein the pneumococcal infection is hemolytic uremia.
77. A composition comprising a pneumococcal neuraminidase or an antigenic portion thereof, a non-phosphocholine antigenic portion of pneumococcal teichoic acid or pneumococcal lipoteichoic acid, and a pharmaceutically acceptable carrier, wherein the composition is suitable for administration to a mucosal surface.
78. The composition of claim 77, wherein the composition is a nasal spray.
79. The composition of claim 77, wherein the composition is a nebulizer solution.
80. The composition of claim 77, wherein the composition is an aerosol inhalant.
81. A container comprising the composition of claim 77.
82. The container of claim 81, wherein the container is a nasal sprayer.
83. The container of claim 81, wherein the container is a nebulizer.
84. The container of claim 81, wherein the container is an inhaler.
85. A method of generating antibodies specific to pneumococcal neuraminidase in a subject comprising contacting the nasal mucosa of the subject with the composition of claim 77.

86. A method of reducing pneumococcal nasal carriage in a subject comprising
contacting the nasal mucosa of the subject with the composition of claim 77.
87. A method of preventing pneumococcal infection in a subject comprising
contacting a mucosal surface of the subject with the composition of claim 77.
88. The method of claim 87 , wherein the pneumococcal infection is meningitis.
89. The method of claim 87 , wherein the pneumococcal infection is otitis media.
90. The method of claim 87 , wherein the pneumococcal infection is pneumonia.
91. The method of claim 87 , wherein the pneumococcal infection is hemolytic uremia.

ABSTRACT

Provided herein are compositions designed to reduce or prevent bacterial infections (for example pneumococcal infections), nasal carriage, nasal colonization, and central nervous system invasion. Provided herein is a composition comprising a

5 pneumococcal neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid, or an antigenic portion of either neuraminidase, phosphocholine, pneumococcal teichoic acid, pneumococcal lipoteichoic acid.

10 Optionally, the composition can comprise any combination of a pneumococcal neuraminidase, a phosphocholine, a pneumococcal teichoic acid, a pneumococcal lipoteichoic acid or an antigenic portion of any one of these. Optionally the agents are detoxified. Further provided are methods of making and using the compositions disclosed herein. Specifically provided are methods of generating antibodies in a subject comprising administering to the subject an agent or composition taught herein.

15 Also provided are methods of reducing or preventing nasal carriage or pneumococcal infection in a subject comprising administering to the subject a composition taught herein.

Docket No:
Title:

21085.0067U1
Composition for
Reducing Bacterial
Carriage and CNS
Invasion and Method of
Using Same
GDS

Attv:




FIGURE 1

Docket No: 21085.0067UI
Title: Composition for
Reducing Bacterial
Carriage and CNS
Invasion and Method of
Using Same
Atty: GDS




FIGURE 2




FIGURE 3

Docket No:
Title:

21085.0067UI
Composition for
Reducing Bacterial
Carriage and CNS
Invasion and Method of
Using Same
GDS

Atty:




FIGURE 4

Docket No: 21085.0067U1
Title: Composition for Reducing Bacterial Carriage and CNS Invasion and Method of Using Same
Atty: GDS




FIGURE 5




FIGURE 6

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/037394

International filing date: 10 November 2004 (10.11.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/518,799
Filing date: 10 November 2003 (10.11.2003)

Date of receipt at the International Bureau: 17 December 2004 (17.12.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.